Axon Enterprise (AXON) 10-Q 6 Nov 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Oct. 30, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3
Entity Registrant Name	TASER INTERNATIONAL INC
Entity Central Index Key	1,069,183
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		53,642,562

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 45,887	$ 48,367
Short-term investments	49,526	32,774
Accounts and notes receivable, net of allowance of $225 and $251 as of September 30, 2015 and December 31, 2014, respectively	24,328	30,735
Inventory, net	18,892	18,323
Prepaid expenses and other current assets	6,336	4,443
Deferred income tax assets, net	5,186	5,186
Total current assets	150,155	139,828
Property and equipment, net of accumulated depreciation of $35,431 and $33,906 as of September 30, 2015 and December 31, 2014, respectively	19,855	17,523
Deferred income tax assets, net	11,147	10,877
Intangible assets, net	7,812	3,115
Goodwill	9,313	2,206
Long-term investments	9,171	9,296
Other assets	6,024	2,523
Total assets	213,477	185,368
Current liabilities:
Accounts payable	6,040	7,682
Accrued liabilities	6,668	9,245
Current portion of deferred revenue	19,628	14,020
Customer deposits	572	988
Current portion of notes payable and capital lease payable	98	38
Total current liabilities	33,006	31,973
Deferred revenue, net of current portion	26,880	21,668
Liability for unrecognized tax benefits	1,198	1,471
Long-term deferred compensation	1,857	1,121
Long-term business acquisition contingent consideration	952	0
Long-term portion of notes payable and capital lease payable	98	29
Total liabilities	$ 63,991	$ 56,262
Commitments and contingencies (Note 10)
Stockholders’ equity:
Preferred stock, $0.00001 par value; 25,000,000 shares authorized; no shares issued and outstanding as of September 30, 2015 and December 31, 2014	$ 0	$ 0
Common stock, $0.00001 par value; 200,000,000 shares authorized; 53,604,818 and 53,000,867 shares issued and outstanding as of September 30, 2015 and December 31, 2014, respectively	1	1
Additional paid-in capital	175,766	162,641
Treasury stock at cost, 18,432,158 and 18,139,958 shares as of September 30, 2015 and December 31, 2014, respectively	(122,201)	(114,645)
Retained earnings	95,874	81,045
Accumulated other comprehensive income	46	64
Total stockholders’ equity	149,486	129,106
Total liabilities and stockholders’ equity	$ 213,477	$ 185,368

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Allowance on accounts receivable	$ 225	$ 251
Accumulated depreciation	$ 35,431	$ 33,906
Preferred stock, par value	$ 0.00001	$ 0.00001
Preferred stock, shares authorized	25,000,000	25,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	53,604,818	53,000,867
Common stock, shares outstanding	53,604,818	53,000,867
Treasury stock, shares	18,432,158	18,139,958

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Statement [Abstract]
Net sales	$ 50,376	$ 44,349	$ 141,851	$ 117,709
Cost of products sold and services delivered	19,308	15,636	50,192	43,574
Gross margin	31,068	28,713	91,659	74,135
Operating expenses:
Sales, general and administrative	17,834	12,441	47,842	39,734
Research and development	6,528	3,759	16,992	10,820
Total operating expenses	24,362	16,200	64,834	50,554
Income from operations	6,706	12,513	26,825	23,581
Interest income and other (expense) income, net	(22)	(160)	12	(88)
Income before provision for income taxes	6,684	12,353	26,837	23,493
Provision for income taxes	5,163	4,795	12,008	8,661
Net income	$ 1,521	$ 7,558	$ 14,829	$ 14,832
Net income per common and common equivalent shares:
Basic (in dollars per share)	$ 0.03	$ 0.14	$ 0.28	$ 0.28
Diluted (in dollars per share)	$ 0.03	$ 0.14	$ 0.27	$ 0.27
Weighted average number of common and common equivalent shares outstanding:
Basic (in shares)	53,709	52,475	53,509	53,013
Diluted (in shares)	54,691	53,821	54,671	54,550
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
Net income	$ 1,521	$ 7,558	$ 14,829	$ 14,832
Foreign currency translation adjustments	(115)	(15)	(18)	0
Comprehensive income	$ 1,406	$ 7,543	$ 14,811	$ 14,832

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash flows from operating activities:
Net income	$ 14,829	$ 14,832
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	2,310	3,368
(Gain) loss on write-down / disposal of property and equipment, net	(13)	17
Loss on disposal of intangibles	216	211
Bond premium amortization	1,252	675
Stock-based compensation	5,086	4,121
Deferred income taxes	(888)	9,862
Unrecognized tax benefits	(273)	(1,713)
Excess tax benefit from stock-based compensation	(6,314)	(5,849)
Change in assets and liabilities:
Accounts and notes receivable	7,718	(4,611)
Inventory	(37)	(5,019)
Prepaid expenses and other assets	(5,520)	(1,063)
Accounts payable, accrued and other liabilities	1,697	(1,188)
Deferred revenue	10,667	9,780
Customer deposits	(416)	(785)
Net cash provided by operating activities	30,314	22,638
Cash flows from investing activities:
Purchases of investments	(50,598)	(23,613)
Proceeds from call / maturity of investments	32,719	8,668
Purchases of property and equipment	(3,839)	(2,066)
Proceeds from disposal of fixed assets	13	10
Purchases of intangible assets	(402)	(125)
Business acquisitions, net of cash acquired	(11,186)
Net cash used in investing activities	(33,293)	(17,126)
Cash flows from financing activities:
Repurchase of common stock	(7,556)	(22,442)
Proceeds from options exercised	2,573	8,597
Payroll tax payments for net-settled stock awards	(848)	(1,262)
Payments on capital lease obligation	(28)	(26)
Payments on notes payable	(26)	0
Excess tax benefit from stock-based compensation	6,314	5,849
Net cash provided by (used in) financing activities	429	(9,284)
Effect of exchange rate changes on cash and cash equivalents	70	116
Net decrease in cash and cash equivalents	(2,480)	(3,656)
Cash and cash equivalents, beginning of period	48,367	42,271
Cash and cash equivalents, end of period	45,887	38,615
Supplemental disclosure:
Cash paid for income taxes, net of refunds	5,830	403
Non-cash transactions
Property and equipment purchases in accounts payable and accrued liabilities	$ 195	$ 158

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Organization and Summary of Significant Accounting Policies	Organization and Summary of Significant Accounting Policies TASER International, Inc. (“TASER” or the “Company”) is a developer and manufacturer of advanced conducted electrical weapons (“CEWs”) designed for use by law enforcement, military, corrections, and private security personnel, and by private individuals for personal defense. In addition, the Company has developed full technology solutions for the capture, storage and management of video/audio evidence as well as other tactical capabilities for use in law enforcement. The Company sells its products worldwide through its direct sales force, distribution partners, online store and third-party resellers. The Company was incorporated in Arizona in September 1993, and reincorporated in Delaware in January 2001. The Company’s corporate headquarters and manufacturing facilities are located in Scottsdale, Arizona. The Company’s software development unit facility is located in Seattle, Washington. The accompanying unaudited condensed consolidated financial statements include the accounts of the Company, and its wholly owned subsidiaries, including TASER International Europe SE (“TASER Europe”), TASER International B.V., and MediaSolv Solutions Corporation ("MediaSolv"). All material intercompany accounts, transactions, and profits have been eliminated. a. Basis of Presentation and Use of Estimates These unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information related to the Company’s organization, significant accounting policies and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) has been condensed or omitted. The accounting policies followed in the preparation of these unaudited condensed consolidated financial statements are consistent with those followed in the Company’s annual consolidated financial statements for the year ended December 31, 2014 , as filed on Form 10-K. In the opinion of management, these unaudited condensed consolidated financial statements contain all material adjustments, consisting only of normal recurring adjustments, necessary to fairly state the Company’s financial position, results of operations and cash flows for the periods presented and the presentations and disclosures herein are adequate when read in conjunction with the Company’s Form 10-K for the year ended December 31, 2014 . The results of operations for the three and nine months ended September 30, 2015 and 2014 are not necessarily indicative of the results to be expected for the full year (or any other period). Significant estimates and assumptions in these unaudited condensed consolidated financial statements include: • product warranty reserves, • inventory valuation reserves, • accounts receivable reserves, • revenue recognition allocated in multiple-deliverable contracts or arrangements, • valuation of goodwill, intangibles and long-lived assets, • recognition, measurement and valuation of current and deferred income taxes, • projection of future taxable income in both United States and foreign jurisdictions for estimating consolidated income tax expense, • fair value of stock awards issued, the estimated vesting period for performance-based stock awards and forfeiture rates, and • recognition and measurement of contingencies and accrued litigation expense. Actual results could differ materially from those estimates. b. Segment Information The Company is comprised of two reportable segments: the manufacture and sale of CEWs, accessories and other products and services (the “TASER Weapons” segment); and the video business which includes the TASER Cam, Axon cameras and related accessories, Evidence.com and MediaSolv (the “Axon” segment). Reportable segments are determined based on discrete financial information reviewed by the Company’s Chief Executive Officer who is the Chief Operating Decision Maker (the “CODM”) for the Company. The Company organizes and reviews operations based on products and services, and currently there are no operating segments that are aggregated. The Company performs an annual analysis of its reportable segments. Additional information related to the Company’s business segments is summarized in Note 13. c. Geographic Information and Major Customers For the three and nine months ended September 30, 2015 and 2014 , net sales by geographic area were as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 United States $ 43,689 86.7 % $ 37,605 84.8 % $ 117,885 83.1 % $ 95,336 81.0 % Other Countries 6,687 13.3 6,744 15.2 23,966 16.9 22,373 19.0 Total $ 50,376 100.0 % $ 44,349 100.0 % $ 141,851 100.0 % $ 117,709 100.0 % Sales to customers outside of the U.S. are typically denominated in U.S. dollars, and are attributed to each country based on the shipping address of the distributor or customer. For the three and nine months ended September 30, 2015 and 2014 , no individual country outside the U.S. represented more than 10% of net sales. Sales in the international market are generally larger and occur more intermittently than in the domestic market due to the profile of the Company's customers. For the three and nine months ended September 30, 2015 and 2014 , no customer represented more than 10% of total net sales. At September 30, 2015 there were two outstanding customer balances from unaffiliated customers that together comprised 24.0% of the aggregate accounts receivable balance. At December 31, 2014 , the Company had a trade receivable from one unaffiliated customer comprising 13.4% of the aggregate accounts receivable balance. d. Income per Common Share Basic income per common share is computed by dividing net income by the weighted average number of common shares outstanding during the periods presented. Diluted income per share reflects the potential dilution that would occur if outstanding stock options were exercised utilizing the treasury stock method. The calculation of the weighted average number of shares outstanding and earnings per share are as follows (in thousands except per share data): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Numerator for basic and diluted earnings per share: Net income $ 1,521 $ 7,558 $ 14,829 $ 14,832 Denominator: Weighted average shares outstanding - basic 53,709 52,475 53,509 53,013 Dilutive effect of stock-based awards 982 1,346 1,162 1,537 Diluted weighted average shares outstanding 54,691 53,821 54,671 54,550 Anti-dilutive stock-based awards excluded 160 336 160 328 Net income per common share: Basic $ 0.03 $ 0.14 $ 0.28 $ 0.28 Diluted $ 0.03 $ 0.14 $ 0.27 $ 0.27 e. Revenue Recognition, Deferred Revenue and Accounts and Notes Receivable The Company derives revenue from two primary sources: (1) the sale of physical products, including CEWs, Axon cameras, corresponding extended warranties, and related accessories such as E-docks, cartridges and batteries, among others, and (2) subscription to the Company's Evidence.com software as a service ("SaaS") (including data storage fees and other ancillary services), which includes varying levels of support. To a lesser extent, the Company also recognizes training and other professional services revenue. Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, title has transferred, the price is fixed and collectability is reasonably assured. Contractual arrangements may contain explicit customer acceptance provisions, and under such arrangements, the Company defers recognition of revenue until formal customer acceptance is received. Extended warranty revenue, SaaS revenue and related data storage revenue are recognized ratably over the term of the contract beginning on the commencement date of each contract. Revenue arrangements with multiple deliverables are divided into separate units and revenue is allocated using the relative selling price method based upon vendor-specific objective evidence of selling price or third-party evidence of the selling prices if vendor-specific objective evidence of selling prices does not exist. If neither vendor-specific objective evidence nor third-party evidence exists, management uses its best estimate of selling price. The majority of the Company’s allocations of arrangement consideration under multiple element arrangements are performed using vendor-specific objective evidence by utilizing prices charged to customers for deliverables when sold separately. The Company’s multiple element arrangements may include future CEWs and/or Axon devices to be delivered at defined points within a multi-year contract, and in those arrangements, the Company allocates total arrangement consideration over the life of the multi-year contract to future deliverables using management’s best estimate of selling price. The Company has not utilized third party evidence of selling price. The Company offers the right to purchase extended warranties that include additional services and coverage beyond the standard limited warranty for certain products. Revenue for extended warranty purchases is deferred at the time of sale and recognized over the warranty period commencing on the date of sale. Extended warranties range from one to five years. Evidence.com and Axon cameras and related accessories have stand-alone value to the customer and are sometimes sold separately, but in most instances are sold together. In these instances, customers typically purchase and pay for the equipment and one year of Evidence.com in advance. Additional years of service are generally billed annually over a specified service term, which has typically ranged from one to five years. Generally, the Company recognizes revenue for the Axon equipment at the time of the sale consistent with the discussion of multiple deliverable arrangements above. Revenue for Evidence.com is deferred at the time of the sale and recognized over the service period. At times the Company subsidizes the cost of Axon devices provided to customers to secure long-term Evidence.com service contracts. In such circumstances, revenue related to the Axon devices recognized at the time of delivery is limited to the amount collected from the customer that is not contingent upon the delivery of future Evidence.com services. The Company recognizes the remaining allocated revenue related to subsidized Axon devices over the remaining period it provides the contracted Evidence.com services. In 2012, the Company introduced a program, the TASER Assurance Program (“TAP”) whereby a customer purchasing a product and joining the program will have the right to trade-in the original product for a new product of the same or like model in the future. Upon joining TAP, customers also receive an extended warranty for the initial products purchased and spare inventory. Under this program the customer generally pays additional annual installments over the contract period, generally three to five years. The Company records consideration received related to the future product purchase as deferred revenue until all revenue recognition criteria are met, which is generally at the end of the contract period. Consideration related to future product purchases is determined at the inception of the arrangement using management’s best estimate of selling price. Management’s estimate is principally based on the current selling price for such products, with due evaluation of the impact of any expected product and pricing changes, which have historically had an immaterial influence on management’s best estimate of selling price. In 2015, The Company introduced the Officer Safety Plan (“OSP”) whereby a customer enters into a five year Evidence.com subscription that includes all of its standard advanced features along with unlimited storage. The OSP also includes a service plan that includes upgrades of (i) the Axon devices every 2.5 years and (ii) a TASER CEW at any point within the contract period. Upon entering into the OSP, customers also receive extended warranties on the Axon and CEW devices over the five-year contract periods as well as spare inventory units. Under this program the customer generally makes an initial purchase of Axon cameras and related accessories, and CEW at inception along with annual installments for services and future hardware deliverables over the contract period. The Company records consideration received related to the future purchase as deferred revenue until all revenue recognition criteria are met, which is generally when the products or services are delivered. Sales tax collected on sales is netted against government remittances and thus, recorded on a net basis. Training and professional service revenues are recorded as the services are provided. Deferred revenue consists of payments received in advance related to products and services for which the criteria for revenue recognition have not yet been met. Deferred revenue that will be recognized during the succeeding twelve month period is recorded as current deferred revenue and the remaining portion is recorded as long-term. Deferred revenue does not include future revenue from multi-year contracts for which no invoice has yet been created. Generally, customers are billed in annual installments. See Note 5 for further disclosures about the Company’s deferred revenue. Sales are typically made on credit, and the Company generally does not require collateral. Management performs ongoing credit evaluations of its customers’ financial condition, and maintains an allowance for estimated potential losses. Uncollectible accounts are charged to expense when deemed uncollectible, and accounts and notes receivable are presented net of an allowance for doubtful accounts. This allowance represents management’s best use of estimates, and is based on judgment after considering a number of factors, including third-party credit reports, actual payment history, cash discounts, customer-specific financial information and broader market and economic trends and conditions. The Company may, from time to time, enter into agreements with its customers to finance their purchases with a note receivable that may range in terms up to five years. Sales are recorded at the fair value of the note, which is generally sold and assigned to a third-party financing company. The terms of the assignments are such that the Company expects to receive payment within 30 days of the original sale. The assignments are non-recourse and the Company has no obligations or continuing involvement with the notes receivable. Prior to entering into an assignment, the Company evaluates the credit quality and financial condition of the third-party financing company. The Company does not generally record interest income on notes receivable due to minimal holding periods, nor has the Company recognized significant gains or losses upon the assignment of the notes. As of September 30, 2015 and December 31, 2014 the Company had no outstanding balances under such arrangements. f. Standard Warranties The Company warranties its CEWs, Axon cameras and certain related accessories from manufacturing defects on a limited basis for a period of one year after purchase and, thereafter, will replace any defective unit for a fee. Estimated costs for the standard warranty are charged to cost of products sold and services delivered when revenue is recorded for the related product. Future warranty costs are estimated based on historical data related to returns and warranty costs on a quarterly basis and this rate is applied to current product sales. Historically, reserve amounts have been increased if management becomes aware of a component failure that could result in larger than anticipated returns from customers. The accrued warranty liability expense is reviewed quarterly to verify that it sufficiently reflects the remaining warranty obligations based on the anticipated expenditures over the balance of the warranty obligation period, and adjustments are made when actual warranty claim experience differs from estimates. Costs related to extended warranties are charged to cost of products sold and services delivered when incurred. The reserve for warranty returns is included in accrued liabilities on the accompanying condensed consolidated balance sheets. Changes in the Company’s estimated product warranty liabilities are as follows (in thousands): Nine Months Ended September 30, 2015 2014 Balance, beginning of period $ 675 $ 955 Utilization of accrual (293 ) (646 ) Warranty expense 19 517 Balance, end of period $ 401 $ 826 g. Fair Value of Financial Instruments The Company uses the fair value framework that prioritizes the inputs to valuation techniques for measuring financial assets and liabilities measured on a recurring basis and for non-financial assets and liabilities when these items are re-measured. Fair value is considered to be the exchange price in an orderly transaction between market participants, to sell an asset or transfer a liability at the measurement date. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. The Company categorizes each of its fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are: • Level 1 – Valuation techniques in which all significant inputs are unadjusted quoted prices from active markets for assets or liabilities that are identical to the assets or liabilities being measured. • Level 2 – Valuation techniques in which significant inputs include quoted prices from active markets for assets or liabilities that are similar to the assets or liabilities being measured and/or quoted prices for assets or liabilities that are identical or similar to the assets or liabilities being measured from markets that are not active. Also, model-derived valuations in which all significant inputs and significant value drivers are observable in active markets are Level 2 valuation techniques. • Level 3 – Valuation techniques in which one or more significant inputs or significant value drivers are unobservable. Unobservable inputs are valuation technique inputs that reflect the Company's own assumptions about inputs that market participants would use in pricing an asset or liability. The Company has cash equivalents and investments, which at September 30, 2015 and December 31, 2014 were comprised of money market funds, state and municipal obligations, corporate bonds, and certificates of deposits. See additional disclosure regarding the fair value of the Company’s cash equivalents and investments in Note 2. Included in the balance of other assets as of September 30, 2015 and December 31, 2014 was $1.8 million and $1.1 million , respectively, related to corporate-owned life insurance policies which are used to fund the Company’s deferred compensation plan. The Company determines the fair value of its insurance contracts by obtaining the cash surrender value of the contracts from the issuer, a Level 2 valuation technique. The Company’s financial instruments also include accounts and notes receivable, accounts payable and accrued liabilities. Due to the short-term nature of these instruments, their fair values approximate their carrying values on the accompanying condensed consolidated balance sheets. h. Valuation of Goodwill, Intangibles and Long-lived Assets Management evaluates whether events and circumstances have occurred that indicate the remaining estimated useful life of long-lived assets and identifiable intangible assets may warrant revision or that the remaining balance of these assets may not be recoverable. Such circumstances could include, but are not limited to, a change in the product mix, a change in the way products are created, produced or delivered, or a significant change in the way products are branded and marketed. In performing the review for recoverability, management estimates the future undiscounted cash flows expected to result from the use of the assets and their eventual disposition. The amount of the impairment loss, if impairment exists, is calculated based on the excess of the carrying amounts of the assets over their estimated fair value computed using discounted cash flows. The Company recorded losses on disposal of intangible assets of $0.2 million during each of the nine months ended September 30, 2015 and 2014 . i. Recently Issued Accounting Guidance In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers (Topic 606)” (“ASU 2014-09”). The core principle of ASU 2014-09 provides that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This guidance also requires more detailed disclosures to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The amendments are effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. The Company has not yet determined the impact the adoption of this guidance will have on its financial position, results of operations or cash flows, if any. In June 2014, the FASB issued ASU No. 2014-12, “Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period” (“ASU 2014-12”). The amendments in ASU 2014-12 require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in ASC Topic No. 718, “Compensation—Stock Compensation” (“ASC 718”) as it relates to awards with performance conditions that affect vesting to account for such awards. The amendments are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. The Company does not expect the adoption of this guidance to have any impact on its financial position, results of operations or cash flows. In July 2015, the FASB issued ASU No. 2015-11, "Inventory (Topic 330)" ("ASU 2015-11"). The amendments require that an entity should measure inventory at the lower of cost and net realizable value. Net realizable value is the estimated prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The amendments are effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The amendments should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The Company does not expect the adoption of this guidance to have any impact on its financial position, results of operations or cash flows. In September 2015, the FASB issued ASU No. 2015-16, "Business Combinations (Topic 805)" ("ASU 2015-16"). The amendments require that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. The amendments require that the acquirer record, in the same period’s financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the provisional amounts, calculated as if the accounting had been completed at the acquisition date. The amendments are effective for fiscal years beginning after December 15, 2015, including interim periods within those fiscal years. The amendments should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The Company does not expect the adoption of this guidance to have any impact on its financial position, results of operations or cash flows. j. Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.

Cash, Cash Equivalents and Inve

Cash, Cash Equivalents and Investments	9 Months Ended
	Sep. 30, 2015
Cash and Cash Equivalents [Abstract]
Cash, Cash Equivalents and Investments	Cash, Cash Equivalents and Investments The following tables summarize the Company's cash, cash equivalents, and held-to-maturity investments at September 30, 2015 and December 31, 2014 (in thousands): As of September 30, 2015 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash and Cash Equivalents Short-Term Investments Long-Term Investments Cash $ 45,065 $ — $ — $ 45,065 $ 45,065 $ — $ — Level 1: Money market funds 762 — — 762 762 — — Corporate bonds 36,216 4 (30 ) 36,190 — 34,035 2,181 Subtotal 36,978 4 (30 ) 36,952 762 34,035 2,181 Level 2: State and municipal obligations 18,683 29 (3 ) 18,709 60 12,675 5,948 Certificates of deposit 3,858 — — 3,858 — 2,816 1,042 Subtotal 22,541 29 (3 ) 22,567 60 15,491 6,990 Total $ 104,584 $ 33 $ (33 ) $ 104,584 $ 45,887 $ 49,526 $ 9,171 As of December 31, 2014 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash and Cash Equivalents Short-Term Investments Long-Term Investments Cash $ 44,260 $ — $ — $ 44,260 $ 44,260 $ — $ — Level 1: Money market funds 3,932 — — 3,932 3,932 — — Corporate bonds 20,388 — (34 ) 20,354 — 15,656 4,732 Subtotal 24,320 — (34 ) 24,286 3,932 15,656 4,732 Level 2: State and municipal obligations 19,145 18 — 19,163 175 15,891 3,079 Certificates of deposit 2,712 — — 2,712 — 1,227 1,485 Subtotal 21,857 18 — 21,875 175 17,118 4,564 Total $ 90,437 $ 18 $ (34 ) $ 90,421 $ 48,367 $ 32,774 $ 9,296 The Company believes the unrealized losses on the Company’s investments are due to interest rate fluctuations. As these investments are either short-term in nature, are expected to be redeemed at par value, and/or because the Company has the ability and intent to hold these investments to maturity, the Company does not consider these investments to be other than temporarily impaired at September 30, 2015 . The following table summarizes the amortized cost and fair value of the short-term and long-term investments held by the Company at September 30, 2015 by contractual maturity (in thousands): Amortized Cost Fair Value Due in less than one year $ 49,526 $ 49,512 Due after one year, through two years 9,171 9,185 Due after two years — — Total short-term and long-term investments $ 58,697 $ 58,697

Inventory

Inventory	9 Months Ended
	Sep. 30, 2015
Inventory Disclosure [Abstract]
Inventory	Inventory Inventories are stated at the lower of cost or market. Cost is determined using the weighted average cost of raw materials which approximates the first-in, first-out (“FIFO”) method and includes allocations of manufacturing labor and overhead. Provisions are made to reduce excess, obsolete or slow-moving inventories to their net realizable value. Inventories consisted of the following at September 30, 2015 and December 31, 2014 (in thousands): 2015 2014 Raw materials $ 11,761 $ 12,229 Work-in-process 59 111 Finished goods 9,155 7,337 Reserve for excess and obsolete inventory (2,083 ) (1,354 ) Total inventory $ 18,892 $ 18,323

Goodwill and Intangible Assets

Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and Intangible Assets The changes in the carrying amount of goodwill for the nine months ended September 30, 2015 were as follows (in thousands): Balance, beginning of period $ 2,206 Goodwill acquired 7,141 Foreign currency translation adjustment (34 ) Balance, end of period $ 9,313 Intangible assets (other than goodwill) consisted of the following (in thousands): September 30, 2015 December 31, 2014 Useful Life Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Amortized: Domain names 5 years $ 125 $ (120 ) $ 5 $ 125 $ (114 ) $ 11 Issued patents 4-15 years 1,841 (629 ) 1,212 1,759 (549 ) 1,210 Issued trademarks 3-11 years 594 (238 ) 356 566 (205 ) 361 Customer relationships 4-8 years 1,053 (100 ) 953 — — — Non-compete agreements 3-4 years 467 (36 ) 431 — — — Developed technology 7 years 3,470 (201 ) 3,269 — — — Total amortized 7,550 (1,324 ) 6,226 2,450 (868 ) 1,582 Not amortized: TASER trademark 900 900 900 900 Patents and trademarks pending 686 686 633 633 Total not amortized 1,586 1,586 1,533 1,533 Total intangible assets $ 9,136 $ (1,324 ) $ 7,812 $ 3,983 $ (868 ) $ 3,115 Amortization expense relative to intangible assets for the three months ended September 30, 2015 and 2014 was approximately $284,000 and $71,000 , respectively. Amortization expense relative to intangible assets for the nine months ended September 30, 2015 and 2014 was approximately $495,000 and $153,000 , respectively. Estimated amortization for intangible assets with definitive lives for the remaining three months of 2015 , the next five years ended December 31, and thereafter, is as follows (in thousands): 2015 (remaining three months) $ 295 2016 939 2017 935 2018 922 2019 802 2020 737 Thereafter 1,596 Total $ 6,226

Deferred Revenue

Deferred Revenue	9 Months Ended
	Sep. 30, 2015
Deferred Revenue Disclosure [Abstract]
Deferred Revenue	Deferred Revenue Deferred revenue consisted of the following (in thousands): September 30, 2015 December 31, 2014 Current Long-Term Total Current Long-Term Total Warranty: TASER Weapons $ 7,244 $ 13,373 $ 20,617 $ 6,591 $ 13,809 $ 20,400 Axon 1,679 1,966 3,645 679 894 1,573 8,923 15,339 24,262 7,270 14,703 21,973 Hardware: TASER Weapons 951 1,447 2,398 365 753 1,118 Axon 825 6,093 6,918 491 2,643 3,134 1,776 7,540 9,316 856 3,396 4,252 Axon Services 8,569 4,001 12,570 5,717 3,569 9,286 Other 360 — 360 177 — 177 Total $ 19,628 $ 26,880 $ 46,508 $ 14,020 $ 21,668 $ 35,688 September 30, 2015 December 31, 2014 Current Long-Term Total Current Long-Term Total TASER Weapons $ 8,555 $ 14,820 $ 23,375 $ 7,133 $ 14,562 $ 21,695 Axon 11,073 12,060 23,133 6,887 7,106 13,993 Total $ 19,628 $ 26,880 $ 46,508 $ 14,020 $ 21,668 $ 35,688

Accrued Liabilities

Accrued Liabilities	9 Months Ended
	Sep. 30, 2015
Payables and Accruals [Abstract]
Accrued Liabilities	Accrued Liabilities Accrued liabilities consisted of the following at September 30, 2015 and December 31, 2014 (in thousands): 2015 2014 Accrued salaries and benefits $ 2,957 $ 3,699 Accrued judgments and settlements 65 108 Accrued professional fees 330 257 Accrued warranty expense 401 675 Accrued income and other taxes 712 539 Other accrued expenses 2,203 3,967 Accrued liabilities $ 6,668 $ 9,245

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Deferred Tax Assets Net deferred income tax assets at September 30, 2015 , include capitalized research and development costs, research and development tax credits, non-qualified stock-based compensation expense, deferred warranty revenue, warranty and inventory reserves, accrued vacation, and other items, partially offset by accelerated depreciation expense and intangible amortization that is not tax deductible. The Company’s total current and long-term net deferred tax assets at September 30, 2015 were $16.3 million . In preparing the Company’s condensed consolidated financial statements, management assesses the likelihood that its deferred tax assets will be realized from future taxable income. In evaluating the Company’s ability to recover its deferred income tax assets, management considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction by jurisdiction basis. A valuation allowance is established if it is determined that it is more likely than not that some portion or all of the net deferred tax assets will not be realized. Management exercises significant judgment in determining its provisions for income taxes, its deferred tax assets and liabilities, and its future taxable income for purposes of assessing its ability to utilize any future tax benefit from its deferred tax assets. Although management believes that its tax estimates are reasonable, the ultimate tax determination involves significant judgments that could become subject to audit by tax authorities in the ordinary course of business. As of each reporting date, management considers new evidence, both positive and negative, that could impact management’s view with regards to future realization of deferred tax assets. As of September 30, 2015 , the Company continues to demonstrate three-year cumulative pre-tax income in the U.S. federal and Arizona tax jurisdictions; however, the Arizona R&D Tax Credits start to expire in 2018 with a significant tranche with a gross value of $1.2 million expiring if not used by the end of 2019. Under the Company’s new tax structure, it appears that long term investments which impact short term profits will likely result in some of the R&D credits expiring before they are utilized. Therefore, management has concluded that it is more likely than not that a portion of the Company’s deferred tax assets will not be realized. The Company has completed research and development (“R&D”) tax credit studies which identified approximately $11.1 million in tax credits for federal, Arizona and California income tax purposes related to the 2003 through 2015 tax years. Management has made the determination that it is more likely than not that the full benefit of the R&D tax credit will not be sustained on examination and recorded a liability for unrecognized tax benefits of $2.3 million as of September 30, 2015 . In addition, management accrued approximately $0.1 million for estimated uncertain tax positions related to certain state income tax liabilities as of September 30, 2015 . The Company recently completed an IRS audit for the tax year 2012, and as of September 30, 2015, the amount of unrecognized tax benefits decreased by $0.4 million . The Company does not expect a significant increase or decrease in the total amount of unrecognized tax benefits within 12 months. Should the total unrecognized tax benefit of $2.4 million be recognized, the Company’s effective tax rate would be favorably impacted. Approximately $1.2 million of the unrecognized tax benefit associated with research and development credits has been netted against the research and development credit deferred tax asset. Effective Tax Rate The Company’s overall effective tax rate for the nine months ended September 30, 2015 , after discrete period adjustments, was 44.0% . Before discrete adjustments the tax rate was 45.5% , which is above the statutory rate primarily due to the impact of the relative amounts of income or loss projected in certain foreign jurisdictions, state taxes and non-deductible expenses for items such as ISO stock option expense, meals and entertainment, and lobbying fees, partially offset by the impact of the domestic production activities deduction. The Company has nearly completed the full implementation of its new international structure, which is new for 2015. In accounting for the income tax effects of this new structure, the Company has recognized income tax expense in the current quarter based on the results it expects for the full year. Actual results could be different, impacting the Company’s income tax expense in future quarters.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2015
Equity [Abstract]
Stockholders' Equity	Stockholders’ Equity In May 2013, the Company’s stockholders approved a new stock incentive plan authorizing an additional 1.6 million shares, plus remaining available shares under a prior plan for issuance under the new plan. Combined with the legacy stock incentive plans, there are approximately 1.3 million shares available for grant as of September 30, 2015 . Performance-based stock awards The Company has issued performance-based stock options and performance-based restricted stock units ("RSUs"), the vesting of which is contingent upon the achievement of certain performance criteria related to the operating performance of the Company, as well as successful and timely development and market acceptance of future product introductions. In addition, certain of the performance RSUs have additional service requirements subsequent to the achievement of the performance criteria. Compensation expense is recognized over the implicit service period (the longer of the period the performance condition is expected to be achieved or the required service period) based on management’s estimate of the probability of the performance criteria being satisfied, adjusted at each balance sheet date. Restricted Stock Units The following table summarizes RSU activity for the nine months ended September 30, 2015 (number of units and aggregate intrinsic value in thousands): Number of Units Weighted Average Grant-Date Fair Value Aggregate Units outstanding, beginning of year 1,226 $ 13.23 Granted 400 27.24 Released (399 ) 11.23 Forfeited (101 ) 16.45 Units outstanding, end of period 1,126 18.59 $ 24,801 Aggregate intrinsic value represents the Company’s closing stock price on the last trading day of the period, which was $22.03 per share, multiplied by the number of RSUs outstanding. As of September 30, 2015 , there was $15.8 million in unrecognized compensation costs related to RSUs under the Company's stock plans. The Company expects to recognize the cost related to the RSUs over a weighted average period of 2.73 years . RSUs are released when vesting requirements are met. During the nine months ended September 30, 2015 , the Company granted approximately 36,101 performance-based RSUs, which are included in the table above. As of September 30, 2015 , the performance criteria had not been met for any of the 0.1 million performance-based RSUs outstanding. Certain of the performance-based RSUs granted in 2015 and 2014 contain provisions whereby the amount of RSUs that ultimately vest is dependent upon the level of achievement of performance metrics. The amount of RSUs included in the table above related to such grants is the target level, which is the Company's best estimate of the amount of RSUs that will vest. The maximum additional number of performance-based RSUs that could be earned is 0.1 million , which are not included in the table above. Certain RSUs that vested in the nine months ended September 30, 2015 were net-share settled such that the Company withheld shares with value equivalent to the employees’ minimum statutory obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. Total shares withheld were approximately 33,000 and had a value of approximately $0.8 million on their respective vesting dates as determined by the Company’s closing stock price. Payments for the employees’ tax obligations are reflected as a financing activity within the statement of cash flows. These net-share settlements had the effect of share repurchases by the Company as they reduced the amount of shares that would have otherwise been issued as a result of the vesting. Stock Option Activity The following table summarizes stock option activity for the nine months ended September 30, 2015 (number of units and aggregate intrinsic value in thousands): Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (years) Aggregate Options outstanding, beginning of year 1,641 $ 5.26 Granted — — Exercised (504 ) 4.96 Expired / terminated (8 ) 8.71 Options outstanding, end of period 1,129 5.36 3.60 $ 18,823 Options exercisable, end of period 1,098 5.37 3.61 18,299 Options expected to vest, end of period 25 4.75 3.25 434 Aggregate intrinsic value represents the difference between the exercise price of the underlying stock option awards and the closing market price of the Company's common stock of $22.03 on September 30, 2015 . The intrinsic value of options exercised for the nine months ended September 30, 2015 and 2014 was $13.3 million and $14.4 million , respectively. Options expected to vest are presented net of forfeitures. As of September 30, 2015 , total options outstanding includes approximately 0.2 million performance-based stock options, of which approximately 30,600 were unvested and 25,000 expected to vest. Stock-based Compensation Expense The estimated fair value of stock-based awards is amortized to expense on a straight-line basis over the service periods. As stock-based compensation expense recognized is based on awards ultimately expected to vest, it is reduced for estimated forfeitures. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company’s forfeiture rate was calculated based on its historical experience of awards which ultimately vested. The following table summarizes the composition of stock stock-based compensation for the three and nine months ended September 30, 2015 and 2014 (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Cost of products sold and services delivered $ 118 $ 61 $ 276 $ 149 Sales, general and administrative expenses 1,123 940 2,982 2,598 Research and development expenses 622 436 1,828 1,374 Total stock-based compensation $ 1,863 $ 1,437 $ 5,086 $ 4,121 Stock Repurchase Plan In May 2014, the Company announced that TASER’s Board of Directors authorized a stock repurchase program to acquire up to $30.0 million of the Company’s outstanding common stock subject to stock market conditions and corporate considerations. During the three months ended September 30, 2015 , the Company purchased approximately 0.3 million common shares under the program for a total cost of approximately $7.6 million , or a weighted average cost of $25.86 per share. The weighted average cost includes the average price paid per share of $25.83 , plus any applicable administrative costs for the transaction. As of September 30, 2015 , no amounts remain available under the plan for future purchases.

Line of Credit

Line of Credit	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Line of Credit	Line of Credit The Company has a $10.0 million revolving line of credit with a domestic bank. At both September 30, 2015 and December 31, 2014 , there were no borrowings under the line. As of September 30, 2015 , the Company had letters of credit outstanding of approximately $3.0 million under the facility and available borrowing of approximately $7.0 million . The line is secured by substantially all of the assets of the Company, and bears interest at varying rates (currently LIBOR plus 1.5% or Prime less 0.75% ). The line of credit matures on July 31, 2017 , and requires monthly payments of interest only. The Company’s agreement with the bank requires it to comply with certain financial and other covenants including maintenance of a maximum leverage ratio and minimum fixed charge coverage ratio. The leverage ratio (ratio of total liabilities to tangible net worth) can be no greater than 1 :1, and the fixed charge coverage ratio can be no less than 1.25 :1, based upon a trailing twelve -month period. At September 30, 2015 , the Company’s tangible net worth ratio was 0.48 :1 and its fixed charge coverage ratio was 2.53 :1. Accordingly, the Company was in compliance with these covenants.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Product Litigation The Company is currently named as a defendant in 15 lawsuits in which the plaintiffs allege either wrongful death or personal injury in situations in which a TASER CEW was used (or present) by law enforcement officers in connection with arrests or during training exercises. In addition, one other product litigation matter in which the Company is involved is currently on appeal. While the facts vary from case to case, the product liability claims are typically based on an alleged product defect resulting in injury or death, usually involving a failure to warn, and the plaintiffs are seeking monetary damages. Three recent lawsuits allege fraud and misrepresentation and are seeking punitive damages in addition to compensatory damages. The information throughout this note is current through the filing date of this Quarterly Report on Form 10-Q. As a general rule, it is the Company’s policy not to settle suspect injury or death cases. Exceptions are sometimes made where the settlement is strategically beneficial to the Company. Also, on occasion, the Company’s insurance company has settled such lawsuits over the Company’s objection where the risk is over the Company’s liability insurance deductibles. Due to the confidentiality of the Company's litigation strategy and the confidentiality agreements that are executed in the event of a settlement, it does not identify or comment on which specific lawsuits have been settled or the amount of any settlement. In 2009, the Company implemented new risk management strategies, including revisions to product warnings and training to better protect both the Company and its customers from litigation based on ‘failure to warn’ theories - which comprise the vast majority of the cases against the Company. These risk management strategies have been highly effective in reducing the rate and exposure from litigation post-2009. From the third quarter of 2011 to the third quarter of 2015 , product liability cases have been reduced from 55 active to 16 active cases, including cases currently on appeal. Management believes that pre-2009 cases have a different risk profile than cases which have occurred since the risk management procedures were introduced in 2009. Therefore, the Company necessarily treats certain pre-2009 cases as exceptions to the Company’s general no settlement policy in order to reduce caseload, legal costs and liability exposure. The Company intends to continue its successful practice of aggressively defending and generally not settling litigation except in very limited and unusual circumstances as described above. With respect to each of the pending lawsuits, the following table lists the name of plaintiff, the date the Company was served with process, the jurisdiction in which the case is pending, the type of claim and the status of the matter. Plaintiff Month Served Jurisdiction Claim Type Status Koon Dec-08 17th Judicial Circuit Court, Broward County, FL Training Injury Discovery Phase Derbyshire Nov-09 Ontario, Canada Superior Court of Justice Officer Injury Discovery Phase Thompson Mar-10 11th Judicial Circuit Court, Miami-Dade County, FL Wrongful Death Discovery Phase Doan Apr-10 The Queen's Bench Alberta, Red Deer Judicial Dist. Wrongful Death Discovery Phase Shymko Dec-10 The Queen's Bench, Winnipeg Centre, Manitoba Wrongful Death Pleading Phase Ramsey Jan-12 17th Judicial Circuit Court, Broward County, FL Wrongful Death Discovery Phase Firman Apr-12 Ontario, Canada Superior Court of Justice Wrongful Death Pleading Phase Schrock Sep-14 San Bernardino County Superior Court, CA Wrongful Death Discovery Phase - Trial scheduled July 2016 Moore Nov-14 St. Louis County Circuit Court, MO Wrongful Death Discovery Phase Jones Jan-15 Los Angeles County Superior Court, CA Suspect Injury Discovery Phase - Trial scheduled April 2016 McKelvey Apr-15 US District Court, OR Wrongful Death Pleading Phase - Trial scheduled for October 2016 Price Jul-15 US District Court, OR Wrongful Death Pleading Phase Demery Aug-15 US District Court, LA Wrongful Death Pleading Phase Llach Sep-15 11th Judicial Circuit Court, Miami-Dade County, FL Wrongful Death Pleading Phase Bennett Sep-15 11th Judicial Circuit Court, Miami-Dade County, FL Wrongful Death Pleading Phase In addition, other product litigation matters in which the Company is involved that are currently on appeal are listed below: Plaintiff Month Served Jurisdiction Claim Type Status Mitchell Apr-12 US District Court, ED MI Wrongful Death Company won appeal with three judge panel, petition filed by Plaintiff for full Court of Appeals review There were no cases that were dismissed or judgment entered during the third quarter of 2015 and through the filing date of this Quarterly Report on Form 10-Q. Cases that were dismissed or judgment entered in prior fiscal quarters are not included in this table. The claims, and in some instances the defense, of each of these lawsuits have been submitted to the Company’s insurance carriers that maintained insurance coverage during the applicable periods. The Company continues to maintain product liability insurance coverage with varying limits and deductibles. The following table provides information regarding the Company’s product liability insurance. Remaining insurance coverage is based on information received from the Company’s insurance provider (in millions). Policy Year Policy Start Date Policy End Date Insurance Coverage Deductible Amount Defense Costs Covered Remaining Insurance Coverage Active Cases and Cases on Appeal 2004 12/1/2003 12/1/2004 $ 2.0 $ 0.1 N $ 2.0 n/a 2005 12/1/2004 12/1/2005 10.0 0.3 Y 7.0 n/a 2006 12/1/2005 12/1/2006 10.0 0.3 Y 3.7 n/a 2007 12/1/2006 12/1/2007 10.0 0.3 Y 8.0 n/a 2008 12/1/2007 12/15/2008 10.0 0.5 Y — Koon 2009 12/15/2008 12/15/2009 10.0 1.0 N 10.0 Derbyshire 2010 12/15/2009 12/15/2010 10.0 1.0 N 10.0 Thompson, Shymko, Doan 2011 12/15/2010 12/15/2011 10.0 1.0 N 10.0 n/a Jan-Jun 2012 12/15/2011 6/25/2012 7.0 1.0 N 7.0 Ramsey, Mitchell, Firman Jul-Dec 2012 6/25/2012 12/15/2012 12.0 1.0 N 12.0 n/a 2013 12/15/2012 12/15/2013 12.0 1.0 N 12.0 n/a 2014 12/15/2013 12/15/2014 11.0 4.0 N 11.0 Schrock, Moore 2015 12/15/2014 12/15/2015 10.0 5.0 N 10.0 Jones, McKelvey, Price, Demery, Llach, Bennett General From time to time, the Company is notified that it may be a party to a lawsuit or that a claim is being made against it. It is the Company’s policy to not disclose the specifics of any claim or threatened lawsuit until the summons and complaint are actually served on the Company. After carefully assessing the claim, and assuming the Company determines that it is not at fault or it disagrees with the damages or relief demanded, the Company vigorously defend any lawsuit filed against the Company. In certain legal matters, the Company records a liability when losses are deemed probable and reasonably estimable. In evaluating matters for accrual and disclosure purposes, the Company takes into consideration factors such as our historical experience with matters of a similar nature, the specific facts and circumstances asserted, the likelihood of our prevailing, and the severity of any potential loss. the Company reevaluates and updates our accruals as matters progress over time. Based on the Company's assessment of outstanding litigation and claims as of September 30, 2015 , the Company has determined that it is not reasonably possible that these lawsuits will individually, or in the aggregate, materially affect its results of operations, financial condition or cash flows. However, the outcome of any litigation is inherently uncertain and there can be no assurance that any expense, liability or damages that may ultimately result from the resolution of these matters will be covered by its insurance or will not be in excess of amounts recognized or provided by insurance coverage and will not have a material adverse effect on our operating results, financial condition or cash flows. Off-Balance Sheet Arrangements Under certain circumstances, the Company uses letters of credit and surety bonds to guarantee its performance under various contracts, principally in connection with the installation and integration of its Axon cameras and related technologies. Certain of the Company's letters of credit contracts and surety bonds have stated expiration dates with others being released as the contractual performance terms are completed. At September 30, 2015 , the Company had outstanding letters of credit of approximately $3.0 million . Of that amount, $2.7 million is expected to expire in May 2017 and $0.3 million is expected to expire in January 2017. Additionally, the Company had approximately $2.4 million of outstanding surety bonds at September 30, 2015 , with $2.2 million expiring in July 2018 and the remaining $0.2 million expected to be released in the near term.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2015
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions The Company engages Dr. Mark Kroll, a member of the Board of Directors, to provide consulting services. The expenses related to these services were approximately $44,000 and $50,000 for the three months ended September 30, 2015 and 2014 , respectively, and $156,000 and $121,000 for the nine months ended September 30, 2015 and 2014 , respectively. At September 30, 2015 and December 31, 2014 , the Company had accrued liabilities of approximately $19,000 and $8,000 , respectively, related to these services. The Company subscribes to a mobile collaboration software suite co-founded and managed by Bret Taylor, a member of the Board of Directors. The Company licenses the software for approximately $20,000 per quarter, and as of September 30, 2015 had prepaid costs related to an annual subscription of approximately $57,000 . No such deferred costs were recorded at December 31, 2014 . In connection with the acquisition of Tactical Safety Responses Limited (Note 14), the Company assumed two long-term non-cancellable operating leases for business premises with the former owners who are now employees of the Company. The leases have an average remaining contractual term 15 years and require aggregate annual rental payments of approximately $45,000 . Prepaid rental payments as of September 30, 2015 were negligible.

Employee Benefit Plans

Employee Benefit Plans	9 Months Ended
	Sep. 30, 2015
Compensation and Retirement Disclosure [Abstract]
Employee Benefit Plans	Employee Benefit Plans The Company has a defined contribution profit sharing 401 (k) plan for eligible employees, which is qualified under Sections 401 (a) and 401 (k) of the Internal Revenue Code of 1986, as amended. Employees are entitled to make tax-deferred contributions of up to the maximum allowed by law of their eligible compensation. The Company also has a non-qualified deferred compensation plan for certain executives, key employees and non-employee directors through which participants may elect to postpone the receipt and taxation of a portion of their compensation, including stock-based compensation, received from the Company. The non-qualified deferred compensation plan allows eligible participants to defer up to 80% of their base salary and up to 100% of other types of compensation. The plan also allows for (i) matching and discretionary employer contributions and (ii) the deferral of vested RSU awards. Employee deferrals are deemed 100% vested upon contribution. Distributions from the plan are made upon retirement, death, separation of service, specified date or upon the occurrence of an unforeseeable emergency. Distributions can be paid in a variety of forms from lump sum to installments over a period of years. Participants in the plan are entitled to select from a wide variety of investments available under the plan and are allocated gains or losses based upon the performance of the investments selected by the participant. All gains or losses are allocated fully to plan participants and the Company does not guarantee a rate of return on deferred balances. Assets related to this plan consist of corporate-owned life insurance contracts and are included in other assets in the condensed consolidated balance sheets. Participants have no rights or claims with respect to any plan assets and any such assets are subject to the claims of the Company’s general creditors. Contributions to the plans are made by both the employee and the Company. Company contributions are based on the level of employee contributions and are immediately vested. The Company’s matching contributions to the 401(k) plan for the three months ended September 30, 2015 and 2014 , were approximately $0.3 million and $0.2 million , respectively. The Company’s matching contributions to the 401(k) plan for the nine months ended September 30, 2015 and 2014 , were approximately $0.9 million and $0.6 million , respectively. The Company expects to make contributions to the non-qualified deferred compensation plan related to the three and nine months ended September 30, 2015 , of approximately $8,000 and $31,000 , respectively. Future matching or profit sharing contributions to the plans are at the Company’s sole discretion.

Segment Data

Segment Data	9 Months Ended
	Sep. 30, 2015
Segment Reporting [Abstract]
Segment Data	Segment Data The Company’s operations are comprised of two reportable segments: the manufacture and sale of CEWs, accessories and other products and services (the “TASER Weapons” segment); and the video business, which includes the TASER Cam, Axon products, Evidence.com, and MediaSolv (the “Axon” segment). The Company includes only revenues and costs directly attributable to the Axon segment in that segment. Included in Axon segment costs are: costs of sales for both products and services, overhead allocation based on direct labor, selling expense for the Axon sales team, Axon product management expenses, trade shows and related expenses, and research and development for products included in the Axon segment. All other costs are included in the TASER Weapons segment. The CODM does not review assets by segment as part of the financial information provided; therefore, only limited asset information is provided in the following tables. Information relative to the Company’s reportable segments is as follows (in thousands): Three Months Ended September 30, 2015 Three Months Ended September 30, 2014 TASER Weapons Axon Total TASER Weapons Axon Total Product sales $ 39,520 $ 7,745 $ 47,265 $ 40,010 $ 3,181 $ 43,191 Service revenue — 3,111 3,111 — 1,158 1,158 Net sales 39,520 10,856 50,376 40,010 4,339 44,349 Cost of products sold 12,445 5,829 18,274 12,443 2,695 15,138 Cost of services delivered — 1,034 1,034 — 498 498 Gross margin 27,075 3,993 31,068 27,567 1,146 28,713 Sales, general and administrative 11,941 5,893 17,834 10,028 2,413 12,441 Research and development 1,151 5,377 6,528 1,050 2,709 3,759 Income (loss) from operations $ 13,983 $ (7,277 ) $ 6,706 $ 16,489 $ (3,976 ) $ 12,513 Purchase of property and equipment $ 1,900 $ 169 $ 2,069 $ 803 $ 41 $ 844 Purchase of intangible assets 114 87 201 14 2 16 Purchase of property and equipment and intangible assets in connection with business acquisitions 1,503 1,502 3,005 — — — Depreciation and amortization 603 345 948 1,010 91 1,101 Nine Months Ended September 30, 2015 Nine Months Ended September 30, 2014 TASER Weapons Axon Total TASER Weapons Axon Total Product sales $ 115,686 $ 18,177 $ 133,863 $ 105,160 $ 9,812 $ 114,972 Service revenue — 7,988 7,988 — 2,737 2,737 Net sales 115,686 26,165 141,851 105,160 12,549 117,709 Cost of products sold 34,805 12,692 47,497 34,024 8,111 42,135 Cost of services delivered — 2,695 2,695 — 1,439 1,439 Gross margin 80,881 10,778 91,659 71,136 2,999 74,135 Sales, general and administrative 33,469 14,373 47,842 32,218 7,516 39,734 Research and development 3,418 13,574 16,992 2,660 8,160 10,820 Income (loss) from operations $ 43,994 $ (17,169 ) $ 26,825 $ 36,258 $ (12,677 ) $ 23,581 Purchase of property and equipment $ 2,435 $ 1,404 $ 3,839 $ 1,836 $ 230 $ 2,066 Purchase of intangible assets 195 207 402 123 2 125 Purchase of property and equipment and intangible assets in connection with business acquisitions 1,503 11,301 12,804 — — — Depreciation and amortization 1,689 621 2,310 3,078 290 3,368

Business Acquisitions

Business Acquisitions	9 Months Ended
	Sep. 30, 2015
Business Acquisition [Abstract]
Business Acquisitions	Business Acquisitions MediaSolv Solutions Corporation On May 5, 2015, the Company acquired all of the outstanding capital stock of MediaSolv Solutions Corporation, a Delaware corporation for a total purchase price of $8.8 million , net of $0.1 million of cash acquired. MediaSolv primarily provides solutions for interview room video, closed-circuit television ("CCTV") and on-premise digital evidence management. These products will connect with the Company's Axon on-officer cameras and, in some cases, its Evidence.com cloud platform, further enabling law enforcement to unify existing silos of digital media and evidence into a seamless workflow from capture to the courtroom. The Company believes the acquisition will also allow the Company to leverage MediaSolv’s existing network and relationships to further strengthen its position in the market. The purchase price consisted primarily of cash, net of cash acquired and working capital adjustments, of $7.8 million and contingent consideration of $1.0 million representing potential earn-outs to former stockholders based on predetermined future financial metrics. The Company also agreed to additional earn-out provisions and compensation adjustments totaling approximately $4.0 million based, in part, on predefined future financial metrics. The earn-outs are not included as part of the purchase price and will be expensed as compensation in the period earned. The fair value of the contingent consideration liability was estimated using a discounted cash flow technique with significant inputs that are not observable in the market and thus represents a Level 3 fair value measurement as defined in ASC 820, Fair Value Measurements and Disclosures. The significant inputs in the Level 3 measurement not supported by market activity included primarily probability assessments related to the attainment of new customers during the earn-out period, appropriately discounted considering the uncertainties associated with the obligation. Subsequent to the date of acquisition, there was no significant change in the estimated fair value of the liability. The Company's purchase price allocation is preliminary and subject to revision as more detailed analyses are completed and additional information about fair value of assets and liabilities become available, including additional information relating to tax matters and finalization of the valuation of identifiable intangible assets. The major classes of assets and liabilities to which the Company has allocated the purchase price, on a preliminary basis, are as follows (in thousands): Accounts receivable and other current assets $ 590 Inventory 35 Property and equipment 53 Intangible assets 4,145 Goodwill 5,600 Accounts payable and accrued liabilities (403 ) Deferred revenue (153 ) Deferred income tax liabilities, net (1,044 ) Total purchase price $ 8,823 The Company has assigned the goodwill to the Axon segment. Other identifiable definite lived intangible assets were assigned a total weighted average amortization period of 6.5 years . MediaSolv has been included in the Company's consolidated results of operations subsequent to the acquisition date. Pro forma results of operations for MediaSolv have not been presented because they are not material to the consolidated results of operations. In connection with the acquisition, the Company incurred and expensed costs of approximately $0.2 million , which included legal, accounting and other third-party expenses related to the transaction. Tactical Safety Responses Limited On July 16, 2015, TASER International B.V., a wholly owned subsidiary of the Company, acquired all of the outstanding capital stock of Tactical Safety Responses Limited ("TSR"), a United Kingdom ("UK") corporation. TSR is the Company's licensed distributor of TASER CEWs and Axon cameras and related accessories in the UK. The acquisition is intended to help expand the Company's growth across the UK by growing its in-country sales and support team. The total purchase was $3.3 million consisting of $4.0 million cash at close, net of $0.7 million of cash acquired. The Company also agreed to additional amounts in the form of earn-outs, subject to the achievement of predefined performance metrics. The earn-outs are not included as part of the purchase price and will be expensed as compensation in the period earned. The acquired entity will operate under the name Axon Public Safety UK. The Company's purchase price allocation is preliminary and subject to revision as more detailed analyses are completed and additional information about fair value of assets and liabilities become available, including additional information relating to tax matters and finalization of the valuation of identifiable intangible assets. The major classes of assets and liabilities to which the Company has allocated the purchase price, on a preliminary basis, are as follows (in thousands): Accounts receivable $ 726 Inventory 497 Property and equipment 583 Other Assets 20 Intangible assets 881 Goodwill 1,541 Accounts payable and accrued liabilities (207 ) Notes payable (169 ) Income tax liabilities (538 ) Total purchase price $ 3,334 The Company has assigned the goodwill to the consolidated entity. Other identifiable definite lived intangible assets were assigned a total weighted average amortization period of 7.0 years. TSR has been included in the Company's consolidated results of operations subsequent to the acquisition date. Pro forma results of operations for TSR have not been presented because they are not material to the consolidated results of operations. In connection with the acquisition, the Company incurred and expensed costs of approximately $0.1 million , which included legal, accounting and other third-party expenses related to the transaction.

Organization and Summary of S20

Organization and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Basis of Presentation and Use of Estimates	Basis of Presentation and Use of Estimates These unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information related to the Company’s organization, significant accounting policies and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) has been condensed or omitted. The accounting policies followed in the preparation of these unaudited condensed consolidated financial statements are consistent with those followed in the Company’s annual consolidated financial statements for the year ended December 31, 2014 , as filed on Form 10-K. In the opinion of management, these unaudited condensed consolidated financial statements contain all material adjustments, consisting only of normal recurring adjustments, necessary to fairly state the Company’s financial position, results of operations and cash flows for the periods presented and the presentations and disclosures herein are adequate when read in conjunction with the Company’s Form 10-K for the year ended December 31, 2014 . The results of operations for the three and nine months ended September 30, 2015 and 2014 are not necessarily indicative of the results to be expected for the full year (or any other period). Significant estimates and assumptions in these unaudited condensed consolidated financial statements include: • product warranty reserves, • inventory valuation reserves, • accounts receivable reserves, • revenue recognition allocated in multiple-deliverable contracts or arrangements, • valuation of goodwill, intangibles and long-lived assets, • recognition, measurement and valuation of current and deferred income taxes, • projection of future taxable income in both United States and foreign jurisdictions for estimating consolidated income tax expense, • fair value of stock awards issued, the estimated vesting period for performance-based stock awards and forfeiture rates, and • recognition and measurement of contingencies and accrued litigation expense. Actual results could differ materially from those estimates.
Segment Information	Segment Information The Company is comprised of two reportable segments: the manufacture and sale of CEWs, accessories and other products and services (the “TASER Weapons” segment); and the video business which includes the TASER Cam, Axon cameras and related accessories, Evidence.com and MediaSolv (the “Axon” segment). Reportable segments are determined based on discrete financial information reviewed by the Company’s Chief Executive Officer who is the Chief Operating Decision Maker (the “CODM”) for the Company. The Company organizes and reviews operations based on products and services, and currently there are no operating segments that are aggregated. The Company performs an annual analysis of its reportable segments. Additional information related to the Company’s business segments is summarized in Note 13.
Geographic Information and Major Customers	Geographic Information and Major Customers For the three and nine months ended September 30, 2015 and 2014 , net sales by geographic area were as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 United States $ 43,689 86.7 % $ 37,605 84.8 % $ 117,885 83.1 % $ 95,336 81.0 % Other Countries 6,687 13.3 6,744 15.2 23,966 16.9 22,373 19.0 Total $ 50,376 100.0 % $ 44,349 100.0 % $ 141,851 100.0 % $ 117,709 100.0 % Sales to customers outside of the U.S. are typically denominated in U.S. dollars, and are attributed to each country based on the shipping address of the distributor or customer.
Income per Common Share	Income per Common Share Basic income per common share is computed by dividing net income by the weighted average number of common shares outstanding during the periods presented. Diluted income per share reflects the potential dilution that would occur if outstanding stock options were exercised utilizing the treasury stock method.
Revenue Recognition, Deferred Revenue and Accounts and Notes Receivable	Revenue Recognition, Deferred Revenue and Accounts and Notes Receivable The Company derives revenue from two primary sources: (1) the sale of physical products, including CEWs, Axon cameras, corresponding extended warranties, and related accessories such as E-docks, cartridges and batteries, among others, and (2) subscription to the Company's Evidence.com software as a service ("SaaS") (including data storage fees and other ancillary services), which includes varying levels of support. To a lesser extent, the Company also recognizes training and other professional services revenue. Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, title has transferred, the price is fixed and collectability is reasonably assured. Contractual arrangements may contain explicit customer acceptance provisions, and under such arrangements, the Company defers recognition of revenue until formal customer acceptance is received. Extended warranty revenue, SaaS revenue and related data storage revenue are recognized ratably over the term of the contract beginning on the commencement date of each contract. Revenue arrangements with multiple deliverables are divided into separate units and revenue is allocated using the relative selling price method based upon vendor-specific objective evidence of selling price or third-party evidence of the selling prices if vendor-specific objective evidence of selling prices does not exist. If neither vendor-specific objective evidence nor third-party evidence exists, management uses its best estimate of selling price. The majority of the Company’s allocations of arrangement consideration under multiple element arrangements are performed using vendor-specific objective evidence by utilizing prices charged to customers for deliverables when sold separately. The Company’s multiple element arrangements may include future CEWs and/or Axon devices to be delivered at defined points within a multi-year contract, and in those arrangements, the Company allocates total arrangement consideration over the life of the multi-year contract to future deliverables using management’s best estimate of selling price. The Company has not utilized third party evidence of selling price. The Company offers the right to purchase extended warranties that include additional services and coverage beyond the standard limited warranty for certain products. Revenue for extended warranty purchases is deferred at the time of sale and recognized over the warranty period commencing on the date of sale. Extended warranties range from one to five years. Evidence.com and Axon cameras and related accessories have stand-alone value to the customer and are sometimes sold separately, but in most instances are sold together. In these instances, customers typically purchase and pay for the equipment and one year of Evidence.com in advance. Additional years of service are generally billed annually over a specified service term, which has typically ranged from one to five years. Generally, the Company recognizes revenue for the Axon equipment at the time of the sale consistent with the discussion of multiple deliverable arrangements above. Revenue for Evidence.com is deferred at the time of the sale and recognized over the service period. At times the Company subsidizes the cost of Axon devices provided to customers to secure long-term Evidence.com service contracts. In such circumstances, revenue related to the Axon devices recognized at the time of delivery is limited to the amount collected from the customer that is not contingent upon the delivery of future Evidence.com services. The Company recognizes the remaining allocated revenue related to subsidized Axon devices over the remaining period it provides the contracted Evidence.com services. In 2012, the Company introduced a program, the TASER Assurance Program (“TAP”) whereby a customer purchasing a product and joining the program will have the right to trade-in the original product for a new product of the same or like model in the future. Upon joining TAP, customers also receive an extended warranty for the initial products purchased and spare inventory. Under this program the customer generally pays additional annual installments over the contract period, generally three to five years. The Company records consideration received related to the future product purchase as deferred revenue until all revenue recognition criteria are met, which is generally at the end of the contract period. Consideration related to future product purchases is determined at the inception of the arrangement using management’s best estimate of selling price. Management’s estimate is principally based on the current selling price for such products, with due evaluation of the impact of any expected product and pricing changes, which have historically had an immaterial influence on management’s best estimate of selling price. In 2015, The Company introduced the Officer Safety Plan (“OSP”) whereby a customer enters into a five year Evidence.com subscription that includes all of its standard advanced features along with unlimited storage. The OSP also includes a service plan that includes upgrades of (i) the Axon devices every 2.5 years and (ii) a TASER CEW at any point within the contract period. Upon entering into the OSP, customers also receive extended warranties on the Axon and CEW devices over the five-year contract periods as well as spare inventory units. Under this program the customer generally makes an initial purchase of Axon cameras and related accessories, and CEW at inception along with annual installments for services and future hardware deliverables over the contract period. The Company records consideration received related to the future purchase as deferred revenue until all revenue recognition criteria are met, which is generally when the products or services are delivered. Sales tax collected on sales is netted against government remittances and thus, recorded on a net basis. Training and professional service revenues are recorded as the services are provided. Deferred revenue consists of payments received in advance related to products and services for which the criteria for revenue recognition have not yet been met. Deferred revenue that will be recognized during the succeeding twelve month period is recorded as current deferred revenue and the remaining portion is recorded as long-term. Deferred revenue does not include future revenue from multi-year contracts for which no invoice has yet been created. Generally, customers are billed in annual installments. See Note 5 for further disclosures about the Company’s deferred revenue. Sales are typically made on credit, and the Company generally does not require collateral. Management performs ongoing credit evaluations of its customers’ financial condition, and maintains an allowance for estimated potential losses. Uncollectible accounts are charged to expense when deemed uncollectible, and accounts and notes receivable are presented net of an allowance for doubtful accounts. This allowance represents management’s best use of estimates, and is based on judgment after considering a number of factors, including third-party credit reports, actual payment history, cash discounts, customer-specific financial information and broader market and economic trends and conditions. The Company may, from time to time, enter into agreements with its customers to finance their purchases with a note receivable that may range in terms up to five years. Sales are recorded at the fair value of the note, which is generally sold and assigned to a third-party financing company. The terms of the assignments are such that the Company expects to receive payment within 30 days of the original sale. The assignments are non-recourse and the Company has no obligations or continuing involvement with the notes receivable. Prior to entering into an assignment, the Company evaluates the credit quality and financial condition of the third-party financing company. The Company does not generally record interest income on notes receivable due to minimal holding periods, nor has the Company recognized significant gains or losses upon the assignment of the notes.
Standard Warranties	Standard Warranties The Company warranties its CEWs, Axon cameras and certain related accessories from manufacturing defects on a limited basis for a period of one year after purchase and, thereafter, will replace any defective unit for a fee. Estimated costs for the standard warranty are charged to cost of products sold and services delivered when revenue is recorded for the related product. Future warranty costs are estimated based on historical data related to returns and warranty costs on a quarterly basis and this rate is applied to current product sales. Historically, reserve amounts have been increased if management becomes aware of a component failure that could result in larger than anticipated returns from customers. The accrued warranty liability expense is reviewed quarterly to verify that it sufficiently reflects the remaining warranty obligations based on the anticipated expenditures over the balance of the warranty obligation period, and adjustments are made when actual warranty claim experience differs from estimates. Costs related to extended warranties are charged to cost of products sold and services delivered when incurred. The reserve for warranty returns is included in accrued liabilities on the accompanying condensed consolidated balance sheets.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company uses the fair value framework that prioritizes the inputs to valuation techniques for measuring financial assets and liabilities measured on a recurring basis and for non-financial assets and liabilities when these items are re-measured. Fair value is considered to be the exchange price in an orderly transaction between market participants, to sell an asset or transfer a liability at the measurement date. The hierarchy below lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market. The Company categorizes each of its fair value measurements in one of these three levels based on the lowest level input that is significant to the fair value measurement in its entirety. These levels are: • Level 1 – Valuation techniques in which all significant inputs are unadjusted quoted prices from active markets for assets or liabilities that are identical to the assets or liabilities being measured. • Level 2 – Valuation techniques in which significant inputs include quoted prices from active markets for assets or liabilities that are similar to the assets or liabilities being measured and/or quoted prices for assets or liabilities that are identical or similar to the assets or liabilities being measured from markets that are not active. Also, model-derived valuations in which all significant inputs and significant value drivers are observable in active markets are Level 2 valuation techniques. • Level 3 – Valuation techniques in which one or more significant inputs or significant value drivers are unobservable. Unobservable inputs are valuation technique inputs that reflect the Company's own assumptions about inputs that market participants would use in pricing an asset or liability. The Company has cash equivalents and investments, which at September 30, 2015 and December 31, 2014 were comprised of money market funds, state and municipal obligations, corporate bonds, and certificates of deposits. See additional disclosure regarding the fair value of the Company’s cash equivalents and investments in Note 2. Included in the balance of other assets as of September 30, 2015 and December 31, 2014 was $1.8 million and $1.1 million , respectively, related to corporate-owned life insurance policies which are used to fund the Company’s deferred compensation plan. The Company determines the fair value of its insurance contracts by obtaining the cash surrender value of the contracts from the issuer, a Level 2 valuation technique. The Company’s financial instruments also include accounts and notes receivable, accounts payable and accrued liabilities. Due to the short-term nature of these instruments, their fair values approximate their carrying values on the accompanying condensed consolidated balance sheets.
Valuation of Goodwill, Intangibles and Long-lived Assets	Valuation of Goodwill, Intangibles and Long-lived Assets Management evaluates whether events and circumstances have occurred that indicate the remaining estimated useful life of long-lived assets and identifiable intangible assets may warrant revision or that the remaining balance of these assets may not be recoverable. Such circumstances could include, but are not limited to, a change in the product mix, a change in the way products are created, produced or delivered, or a significant change in the way products are branded and marketed. In performing the review for recoverability, management estimates the future undiscounted cash flows expected to result from the use of the assets and their eventual disposition. The amount of the impairment loss, if impairment exists, is calculated based on the excess of the carrying amounts of the assets over their estimated fair value computed using discounted cash flows.
Recently Issued Accounting Guidance	Recently Issued Accounting Guidance In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers (Topic 606)” (“ASU 2014-09”). The core principle of ASU 2014-09 provides that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This guidance also requires more detailed disclosures to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The amendments are effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. The Company has not yet determined the impact the adoption of this guidance will have on its financial position, results of operations or cash flows, if any. In June 2014, the FASB issued ASU No. 2014-12, “Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period” (“ASU 2014-12”). The amendments in ASU 2014-12 require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in ASC Topic No. 718, “Compensation—Stock Compensation” (“ASC 718”) as it relates to awards with performance conditions that affect vesting to account for such awards. The amendments are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. The Company does not expect the adoption of this guidance to have any impact on its financial position, results of operations or cash flows. In July 2015, the FASB issued ASU No. 2015-11, "Inventory (Topic 330)" ("ASU 2015-11"). The amendments require that an entity should measure inventory at the lower of cost and net realizable value. Net realizable value is the estimated prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The amendments are effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The amendments should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The Company does not expect the adoption of this guidance to have any impact on its financial position, results of operations or cash flows. In September 2015, the FASB issued ASU No. 2015-16, "Business Combinations (Topic 805)" ("ASU 2015-16"). The amendments require that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. The amendments require that the acquirer record, in the same period’s financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the provisional amounts, calculated as if the accounting had been completed at the acquisition date. The amendments are effective for fiscal years beginning after December 15, 2015, including interim periods within those fiscal years. The amendments should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The Company does not expect the adoption of this guidance to have any impact on its financial position, results of operations or cash flows.
Reclassification of Prior Year Presentation	Reclassification of Prior Year Presentation Certain prior year amounts have been reclassified for consistency with the current year presentation. These reclassifications had no effect on the reported results of operations.

Organization and Summary of S21

Organization and Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2015
Accounting Policies [Abstract]
Net Sales by Geographic Area	For the three and nine months ended September 30, 2015 and 2014 , net sales by geographic area were as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 United States $ 43,689 86.7 % $ 37,605 84.8 % $ 117,885 83.1 % $ 95,336 81.0 % Other Countries 6,687 13.3 6,744 15.2 23,966 16.9 22,373 19.0 Total $ 50,376 100.0 % $ 44,349 100.0 % $ 141,851 100.0 % $ 117,709 100.0 %
Weighted Average Number of Shares Outstanding and Income Per Share	The calculation of the weighted average number of shares outstanding and earnings per share are as follows (in thousands except per share data): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Numerator for basic and diluted earnings per share: Net income $ 1,521 $ 7,558 $ 14,829 $ 14,832 Denominator: Weighted average shares outstanding - basic 53,709 52,475 53,509 53,013 Dilutive effect of stock-based awards 982 1,346 1,162 1,537 Diluted weighted average shares outstanding 54,691 53,821 54,671 54,550 Anti-dilutive stock-based awards excluded 160 336 160 328 Net income per common share: Basic $ 0.03 $ 0.14 $ 0.28 $ 0.28 Diluted $ 0.03 $ 0.14 $ 0.27 $ 0.27
Summary of Changes in Estimated Product Warranty Liabilities	Changes in the Company’s estimated product warranty liabilities are as follows (in thousands): Nine Months Ended September 30, 2015 2014 Balance, beginning of period $ 675 $ 955 Utilization of accrual (293 ) (646 ) Warranty expense 19 517 Balance, end of period $ 401 $ 826

Cash, Cash Equivalents and In22

Cash, Cash Equivalents and Investments (Tables)	9 Months Ended
	Sep. 30, 2015
Cash and Cash Equivalents [Abstract]
Summary of Cash, Cash Equivalents and Held-to-Maturity Investments by Type	The following tables summarize the Company's cash, cash equivalents, and held-to-maturity investments at September 30, 2015 and December 31, 2014 (in thousands): As of September 30, 2015 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash and Cash Equivalents Short-Term Investments Long-Term Investments Cash $ 45,065 $ — $ — $ 45,065 $ 45,065 $ — $ — Level 1: Money market funds 762 — — 762 762 — — Corporate bonds 36,216 4 (30 ) 36,190 — 34,035 2,181 Subtotal 36,978 4 (30 ) 36,952 762 34,035 2,181 Level 2: State and municipal obligations 18,683 29 (3 ) 18,709 60 12,675 5,948 Certificates of deposit 3,858 — — 3,858 — 2,816 1,042 Subtotal 22,541 29 (3 ) 22,567 60 15,491 6,990 Total $ 104,584 $ 33 $ (33 ) $ 104,584 $ 45,887 $ 49,526 $ 9,171 As of December 31, 2014 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value Cash and Cash Equivalents Short-Term Investments Long-Term Investments Cash $ 44,260 $ — $ — $ 44,260 $ 44,260 $ — $ — Level 1: Money market funds 3,932 — — 3,932 3,932 — — Corporate bonds 20,388 — (34 ) 20,354 — 15,656 4,732 Subtotal 24,320 — (34 ) 24,286 3,932 15,656 4,732 Level 2: State and municipal obligations 19,145 18 — 19,163 175 15,891 3,079 Certificates of deposit 2,712 — — 2,712 — 1,227 1,485 Subtotal 21,857 18 — 21,875 175 17,118 4,564 Total $ 90,437 $ 18 $ (34 ) $ 90,421 $ 48,367 $ 32,774 $ 9,296
Summary of Amortized Cost and Fair Value of Short-term and Long-term Investments	The following table summarizes the amortized cost and fair value of the short-term and long-term investments held by the Company at September 30, 2015 by contractual maturity (in thousands): Amortized Cost Fair Value Due in less than one year $ 49,526 $ 49,512 Due after one year, through two years 9,171 9,185 Due after two years — — Total short-term and long-term investments $ 58,697 $ 58,697

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2015
Inventory Disclosure [Abstract]
Inventory	Inventories consisted of the following at September 30, 2015 and December 31, 2014 (in thousands): 2015 2014 Raw materials $ 11,761 $ 12,229 Work-in-process 59 111 Finished goods 9,155 7,337 Reserve for excess and obsolete inventory (2,083 ) (1,354 ) Total inventory $ 18,892 $ 18,323

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The changes in the carrying amount of goodwill for the nine months ended September 30, 2015 were as follows (in thousands): Balance, beginning of period $ 2,206 Goodwill acquired 7,141 Foreign currency translation adjustment (34 ) Balance, end of period $ 9,313
Intangible Assets Other than goodwill	Intangible assets (other than goodwill) consisted of the following (in thousands): September 30, 2015 December 31, 2014 Useful Life Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Amortized: Domain names 5 years $ 125 $ (120 ) $ 5 $ 125 $ (114 ) $ 11 Issued patents 4-15 years 1,841 (629 ) 1,212 1,759 (549 ) 1,210 Issued trademarks 3-11 years 594 (238 ) 356 566 (205 ) 361 Customer relationships 4-8 years 1,053 (100 ) 953 — — — Non-compete agreements 3-4 years 467 (36 ) 431 — — — Developed technology 7 years 3,470 (201 ) 3,269 — — — Total amortized 7,550 (1,324 ) 6,226 2,450 (868 ) 1,582 Not amortized: TASER trademark 900 900 900 900 Patents and trademarks pending 686 686 633 633 Total not amortized 1,586 1,586 1,533 1,533 Total intangible assets $ 9,136 $ (1,324 ) $ 7,812 $ 3,983 $ (868 ) $ 3,115
Estimated Amortization Expense of Intangible Assets	Estimated amortization for intangible assets with definitive lives for the remaining three months of 2015 , the next five years ended December 31, and thereafter, is as follows (in thousands): 2015 (remaining three months) $ 295 2016 939 2017 935 2018 922 2019 802 2020 737 Thereafter 1,596 Total $ 6,226

Deferred Revenue (Tables)

Deferred Revenue (Tables)	9 Months Ended
	Sep. 30, 2015
Deferred Revenue Disclosure [Abstract]
Summary of Deferred Revenue	Deferred revenue consisted of the following (in thousands): September 30, 2015 December 31, 2014 Current Long-Term Total Current Long-Term Total Warranty: TASER Weapons $ 7,244 $ 13,373 $ 20,617 $ 6,591 $ 13,809 $ 20,400 Axon 1,679 1,966 3,645 679 894 1,573 8,923 15,339 24,262 7,270 14,703 21,973 Hardware: TASER Weapons 951 1,447 2,398 365 753 1,118 Axon 825 6,093 6,918 491 2,643 3,134 1,776 7,540 9,316 856 3,396 4,252 Axon Services 8,569 4,001 12,570 5,717 3,569 9,286 Other 360 — 360 177 — 177 Total $ 19,628 $ 26,880 $ 46,508 $ 14,020 $ 21,668 $ 35,688 September 30, 2015 December 31, 2014 Current Long-Term Total Current Long-Term Total TASER Weapons $ 8,555 $ 14,820 $ 23,375 $ 7,133 $ 14,562 $ 21,695 Axon 11,073 12,060 23,133 6,887 7,106 13,993 Total $ 19,628 $ 26,880 $ 46,508 $ 14,020 $ 21,668 $ 35,688

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2015
Payables and Accruals [Abstract]
Accrued Liabilities	Accrued liabilities consisted of the following at September 30, 2015 and December 31, 2014 (in thousands): 2015 2014 Accrued salaries and benefits $ 2,957 $ 3,699 Accrued judgments and settlements 65 108 Accrued professional fees 330 257 Accrued warranty expense 401 675 Accrued income and other taxes 712 539 Other accrued expenses 2,203 3,967 Accrued liabilities $ 6,668 $ 9,245

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2015
Equity [Abstract]
Summary of Restricted Stock Unit Activity	The following table summarizes RSU activity for the nine months ended September 30, 2015 (number of units and aggregate intrinsic value in thousands): Number of Units Weighted Average Grant-Date Fair Value Aggregate Units outstanding, beginning of year 1,226 $ 13.23 Granted 400 27.24 Released (399 ) 11.23 Forfeited (101 ) 16.45 Units outstanding, end of period 1,126 18.59 $ 24,801
Summary of the Company's Stock Options Activity	The following table summarizes stock option activity for the nine months ended September 30, 2015 (number of units and aggregate intrinsic value in thousands): Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (years) Aggregate Options outstanding, beginning of year 1,641 $ 5.26 Granted — — Exercised (504 ) 4.96 Expired / terminated (8 ) 8.71 Options outstanding, end of period 1,129 5.36 3.60 $ 18,823 Options exercisable, end of period 1,098 5.37 3.61 18,299 Options expected to vest, end of period 25 4.75 3.25 434
Reported Share-Based Compensation	The following table summarizes the composition of stock stock-based compensation for the three and nine months ended September 30, 2015 and 2014 (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2015 2014 2015 2014 Cost of products sold and services delivered $ 118 $ 61 $ 276 $ 149 Sales, general and administrative expenses 1,123 940 2,982 2,598 Research and development expenses 622 436 1,828 1,374 Total stock-based compensation $ 1,863 $ 1,437 $ 5,086 $ 4,121

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Loss Contingencies	With respect to each of the pending lawsuits, the following table lists the name of plaintiff, the date the Company was served with process, the jurisdiction in which the case is pending, the type of claim and the status of the matter. Plaintiff Month Served Jurisdiction Claim Type Status Koon Dec-08 17th Judicial Circuit Court, Broward County, FL Training Injury Discovery Phase Derbyshire Nov-09 Ontario, Canada Superior Court of Justice Officer Injury Discovery Phase Thompson Mar-10 11th Judicial Circuit Court, Miami-Dade County, FL Wrongful Death Discovery Phase Doan Apr-10 The Queen's Bench Alberta, Red Deer Judicial Dist. Wrongful Death Discovery Phase Shymko Dec-10 The Queen's Bench, Winnipeg Centre, Manitoba Wrongful Death Pleading Phase Ramsey Jan-12 17th Judicial Circuit Court, Broward County, FL Wrongful Death Discovery Phase Firman Apr-12 Ontario, Canada Superior Court of Justice Wrongful Death Pleading Phase Schrock Sep-14 San Bernardino County Superior Court, CA Wrongful Death Discovery Phase - Trial scheduled July 2016 Moore Nov-14 St. Louis County Circuit Court, MO Wrongful Death Discovery Phase Jones Jan-15 Los Angeles County Superior Court, CA Suspect Injury Discovery Phase - Trial scheduled April 2016 McKelvey Apr-15 US District Court, OR Wrongful Death Pleading Phase - Trial scheduled for October 2016 Price Jul-15 US District Court, OR Wrongful Death Pleading Phase Demery Aug-15 US District Court, LA Wrongful Death Pleading Phase Llach Sep-15 11th Judicial Circuit Court, Miami-Dade County, FL Wrongful Death Pleading Phase Bennett Sep-15 11th Judicial Circuit Court, Miami-Dade County, FL Wrongful Death Pleading Phase
Summary of Other Product Litigation Matters	In addition, other product litigation matters in which the Company is involved that are currently on appeal are listed below: Plaintiff Month Served Jurisdiction Claim Type Status Mitchell Apr-12 US District Court, ED MI Wrongful Death Company won appeal with three judge panel, petition filed by Plaintiff for full Court of Appeals review
Summary of Cases Dismissed or Judgment Entered	third quarter of 2015 and through the filing date of this Quarterly Report on Form 10-Q. Cases that were dismissed or judgment entered in prior fiscal quarters are not included in this table.
Information Regarding the Company's Insurance Coverage	The following table provides information regarding the Company’s product liability insurance. Remaining insurance coverage is based on information received from the Company’s insurance provider (in millions). Policy Year Policy Start Date Policy End Date Insurance Coverage Deductible Amount Defense Costs Covered Remaining Insurance Coverage Active Cases and Cases on Appeal 2004 12/1/2003 12/1/2004 $ 2.0 $ 0.1 N $ 2.0 n/a 2005 12/1/2004 12/1/2005 10.0 0.3 Y 7.0 n/a 2006 12/1/2005 12/1/2006 10.0 0.3 Y 3.7 n/a 2007 12/1/2006 12/1/2007 10.0 0.3 Y 8.0 n/a 2008 12/1/2007 12/15/2008 10.0 0.5 Y — Koon 2009 12/15/2008 12/15/2009 10.0 1.0 N 10.0 Derbyshire 2010 12/15/2009 12/15/2010 10.0 1.0 N 10.0 Thompson, Shymko, Doan 2011 12/15/2010 12/15/2011 10.0 1.0 N 10.0 n/a Jan-Jun 2012 12/15/2011 6/25/2012 7.0 1.0 N 7.0 Ramsey, Mitchell, Firman Jul-Dec 2012 6/25/2012 12/15/2012 12.0 1.0 N 12.0 n/a 2013 12/15/2012 12/15/2013 12.0 1.0 N 12.0 n/a 2014 12/15/2013 12/15/2014 11.0 4.0 N 11.0 Schrock, Moore 2015 12/15/2014 12/15/2015 10.0 5.0 N 10.0 Jones, McKelvey, Price, Demery, Llach, Bennett

Segment Data (Tables)

Segment Data (Tables)	9 Months Ended
	Sep. 30, 2015
Segment Reporting [Abstract]
Summary of Operational Information Relative to the Company's Reportable Segments	Information relative to the Company’s reportable segments is as follows (in thousands): Three Months Ended September 30, 2015 Three Months Ended September 30, 2014 TASER Weapons Axon Total TASER Weapons Axon Total Product sales $ 39,520 $ 7,745 $ 47,265 $ 40,010 $ 3,181 $ 43,191 Service revenue — 3,111 3,111 — 1,158 1,158 Net sales 39,520 10,856 50,376 40,010 4,339 44,349 Cost of products sold 12,445 5,829 18,274 12,443 2,695 15,138 Cost of services delivered — 1,034 1,034 — 498 498 Gross margin 27,075 3,993 31,068 27,567 1,146 28,713 Sales, general and administrative 11,941 5,893 17,834 10,028 2,413 12,441 Research and development 1,151 5,377 6,528 1,050 2,709 3,759 Income (loss) from operations $ 13,983 $ (7,277 ) $ 6,706 $ 16,489 $ (3,976 ) $ 12,513 Purchase of property and equipment $ 1,900 $ 169 $ 2,069 $ 803 $ 41 $ 844 Purchase of intangible assets 114 87 201 14 2 16 Purchase of property and equipment and intangible assets in connection with business acquisitions 1,503 1,502 3,005 — — — Depreciation and amortization 603 345 948 1,010 91 1,101 Nine Months Ended September 30, 2015 Nine Months Ended September 30, 2014 TASER Weapons Axon Total TASER Weapons Axon Total Product sales $ 115,686 $ 18,177 $ 133,863 $ 105,160 $ 9,812 $ 114,972 Service revenue — 7,988 7,988 — 2,737 2,737 Net sales 115,686 26,165 141,851 105,160 12,549 117,709 Cost of products sold 34,805 12,692 47,497 34,024 8,111 42,135 Cost of services delivered — 2,695 2,695 — 1,439 1,439 Gross margin 80,881 10,778 91,659 71,136 2,999 74,135 Sales, general and administrative 33,469 14,373 47,842 32,218 7,516 39,734 Research and development 3,418 13,574 16,992 2,660 8,160 10,820 Income (loss) from operations $ 43,994 $ (17,169 ) $ 26,825 $ 36,258 $ (12,677 ) $ 23,581 Purchase of property and equipment $ 2,435 $ 1,404 $ 3,839 $ 1,836 $ 230 $ 2,066 Purchase of intangible assets 195 207 402 123 2 125 Purchase of property and equipment and intangible assets in connection with business acquisitions 1,503 11,301 12,804 — — — Depreciation and amortization 1,689 621 2,310 3,078 290 3,368

Business Acquisitions (Tables)

Business Acquisitions (Tables)	9 Months Ended
	Sep. 30, 2015
Business Acquisition [Abstract]
Schedule of Business Acquisitions, by Acquisition	The major classes of assets and liabilities to which the Company has allocated the purchase price, on a preliminary basis, are as follows (in thousands): Accounts receivable $ 726 Inventory 497 Property and equipment 583 Other Assets 20 Intangible assets 881 Goodwill 1,541 Accounts payable and accrued liabilities (207 ) Notes payable (169 ) Income tax liabilities (538 ) Total purchase price $ 3,334 The major classes of assets and liabilities to which the Company has allocated the purchase price, on a preliminary basis, are as follows (in thousands): Accounts receivable and other current assets $ 590 Inventory 35 Property and equipment 53 Intangible assets 4,145 Goodwill 5,600 Accounts payable and accrued liabilities (403 ) Deferred revenue (153 ) Deferred income tax liabilities, net (1,044 ) Total purchase price $ 8,823

Organization and Summary of S31

Organization and Summary of Significant Accounting Policies - Additional Information (Detail) $ in Millions	9 Months Ended		12 Months Ended
	Sep. 30, 2015USD ($)SourceDistributor	Sep. 30, 2014USD ($)	Dec. 31, 2014USD ($)Distributor
Summary Of Significant Accounting Policy [Line Items]
Number Of Distributers | Distributor	2		1
Number of revenue sources | Source	2
Company receive payment	30 days
Warranty period	1 year
Corporate owned life insurance policies fair value	$ 1.8		$ 1.1
Goodwill and intangible asset impairment	$ 0.2	$ 0.2
Extended Product Warranty | Minimum
Summary Of Significant Accounting Policy [Line Items]
Service term for services purchased	1 year
Extended Product Warranty | Maximum
Summary Of Significant Accounting Policy [Line Items]
Service term for services purchased	5 years
Evidence. Com
Summary Of Significant Accounting Policy [Line Items]
Subscription period	5 years
Device upgrade period	2 years 6 months
Customer Concentration Risk | Accounts Receivable
Summary Of Significant Accounting Policy [Line Items]
Concentration risk, percentage	24.00%		13.40%

Organization and Summary of S32

Organization and Summary of Significant Accounting Policies - Net Sales by Geographic Area (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Segment Reporting Information [Line Items]
Net sales by Geographic Area	$ 50,376	$ 44,349	$ 141,851	$ 117,709
Percentage of Net sales by Geographic Area	100.00%	100.00%	100.00%	100.00%
United States
Segment Reporting Information [Line Items]
Net sales by Geographic Area	$ 43,689	$ 37,605	$ 117,885	$ 95,336
Percentage of Net sales by Geographic Area	86.70%	84.80%	83.10%	81.00%
Other Countries
Segment Reporting Information [Line Items]
Net sales by Geographic Area	$ 6,687	$ 6,744	$ 23,966	$ 22,373
Percentage of Net sales by Geographic Area	13.30%	15.20%	16.90%	19.00%

Organization and Summary of S33

Organization and Summary of Significant Accounting Policies - Weighted Average Number of Shares Outstanding and Income Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Numerator for basic and diluted earnings per share:
Net income	$ 1,521	$ 7,558	$ 14,829	$ 14,832
Denominator:
Weighted average shares outstanding—basic	53,709	52,475	53,509	53,013
Dilutive effect of stock-based awards (in shares)	982	1,346	1,162	1,537
Diluted weighted average shares outstanding	54,691	53,821	54,671	54,550
Anti-dilutive stock-based awards excluded	160	336	160	328
Net income (loss) per common share:
Basic (in dollars per share)	$ 0.03	$ 0.14	$ 0.28	$ 0.28
Diluted (in dollars per share)	$ 0.03	$ 0.14	$ 0.27	$ 0.27

Organization and Summary of S34

Organization and Summary of Significant Accounting Policies - Summary of Changes in Estimated Product Warranty Liabilities (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Movement in Standard and Extended Product Warranty, Increase (Decrease) [Roll Forward]
Balance, beginning of period	$ 675	$ 955
Utilization of accrual	(293)	(646)
Warranty expense	19	517
Balance, end of period	$ 401	$ 826

Cash, Cash Equivalents, and Inv

Cash, Cash Equivalents, and Investments - Summary of Cash, Cash Equivalents and Held-to-Maturity Investments by Type (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	$ 104,584	$ 90,437
Gross Unrealized Gains	33	18
Gross Unrealized Losses	(33)	(34)
Fair Value	104,584	90,421
Cash and Cash Equivalents	45,887	48,367
Short-term investments	49,526	32,774
Long-term investments	9,171	9,296
State and Municipal Obligations
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	18,683	19,145
Gross Unrealized Gains	29	18
Gross Unrealized Losses	(3)	0
Fair Value	18,709	19,163
Cash and Cash Equivalents	60	175
Short-term investments	12,675	15,891
Long-term investments	5,948	3,079
Certificates of Deposit
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	3,858	2,712
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	3,858	2,712
Cash and Cash Equivalents	0	0
Short-term investments	2,816	1,227
Long-term investments	1,042	1,485
Fair Value, Inputs, Level 1
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	36,978	24,320
Gross Unrealized Gains	4	0
Gross Unrealized Losses	(30)	(34)
Fair Value	36,952	24,286
Cash and Cash Equivalents	762	3,932
Short-term investments	34,035	15,656
Long-term investments	2,181	4,732
Fair Value, Inputs, Level 2
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	22,541	21,857
Gross Unrealized Gains	29	18
Gross Unrealized Losses	(3)	0
Fair Value	22,567	21,875
Cash and Cash Equivalents	60	175
Short-term investments	15,491	17,118
Long-term investments	6,990	4,564
Cash
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	45,065	44,260
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	45,065	44,260
Cash and Cash Equivalents	45,065	44,260
Short-term investments	0	0
Long-term investments	0	0
Money Market Funds
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	762	3,932
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	762	3,932
Cash and Cash Equivalents	762	3,932
Short-term investments	0	0
Long-term investments	0	0
Corporate Bonds
Restricted Cash and Cash Equivalents Items [Line Items]
Amortized Cost	36,216	20,388
Gross Unrealized Gains	4	0
Gross Unrealized Losses	(30)	(34)
Fair Value	36,190	20,354
Cash and Cash Equivalents	0	0
Short-term investments	34,035	15,656
Long-term investments	$ 2,181	$ 4,732

Cash, Cash Equivalents, and I36

Cash, Cash Equivalents, and Investments - Summary of Amortized Cost and Fair Value of Short-term and Long-term Investments (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Due in less than one year	$ 49,526	$ 32,774
Due after one year, through two years	9,171	$ 9,296
Amortized Cost
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Due in less than one year	49,526
Due after one year, through two years	9,171
Due after two years	0
Total short-term and long-term investments	58,697
Fair Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Due in less than one year	49,512
Due after one year, through two years	9,185
Due after two years	0
Total short-term and long-term investments	$ 58,697

Inventory (Detail)

Inventory (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Raw materials	$ 11,761	$ 12,229
Work-in-process	59	111
Finished goods	9,155	7,337
Reserve for excess and obsolete inventory	(2,083)	(1,354)
Total inventory	$ 18,892	$ 18,323

Goodwill and Intangible Asset38

Goodwill and Intangible Assets - Schedule of Goodwill (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2015USD ($)
Goodwill [Roll Forward]
Balance, beginning of period	$ 2,206
Goodwill acquired	7,141
Foreign currency translation adjustment	(34)
Balance, end of period	$ 9,313

Goodwill and Intangible Asset39

Goodwill and Intangible Assets - Intangible Assets Other than Goodwill (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized intangible assets, gross carrying amount	$ 7,550	$ 2,450
Accumulated amortization	(1,324)	(868)
Total	6,226	1,582
Not amortized intangible assets, carrying amount	1,586	1,533
Intangible assets, gross carrying amount	9,136	3,983
Intangible assets, net carrying amount	7,812	3,115
TASER trademark
Acquired Indefinite-lived Intangible Assets [Line Items]
Not amortized intangible assets, carrying amount	900	900
Patents and trademarks pending
Acquired Indefinite-lived Intangible Assets [Line Items]
Not amortized intangible assets, carrying amount	$ 686	633
Domain names
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized intangible assets, useful life	5 years
Amortized intangible assets, gross carrying amount	$ 125	125
Accumulated amortization	(120)	(114)
Total	5	11
Issued patents
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized intangible assets, gross carrying amount	1,841	1,759
Accumulated amortization	(629)	(549)
Total	$ 1,212	1,210
Issued patents | Minimum
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized intangible assets, useful life	4 years
Issued patents | Maximum
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized intangible assets, useful life	15 years
Issued trademarks
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized intangible assets, gross carrying amount	$ 594	566
Accumulated amortization	(238)	(205)
Total	$ 356	361
Issued trademarks | Minimum
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized intangible assets, useful life	3 years
Issued trademarks | Maximum
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized intangible assets, useful life	11 years
Customer relationships
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized intangible assets, gross carrying amount	$ 1,053	0
Accumulated amortization	(100)	0
Total	$ 953	0
Customer relationships | Minimum
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized intangible assets, useful life	4 years
Customer relationships | Maximum
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized intangible assets, useful life	8 years
Non-compete agreements
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized intangible assets, gross carrying amount	$ 467	0
Accumulated amortization	(36)	0
Total	$ 431	0
Non-compete agreements | Minimum
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized intangible assets, useful life	4 years
Non-compete agreements | Maximum
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized intangible assets, useful life	7 years
Developed technology
Acquired Indefinite-lived Intangible Assets [Line Items]
Amortized intangible assets, useful life	7 years
Amortized intangible assets, gross carrying amount	$ 3,470	0
Accumulated amortization	(201)	0
Total	$ 3,269	$ 0

Goodwill and Intangible asset40

Goodwill and Intangible assets - Estimated Amortization Expense of Intangible Assets (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
2015 (remaining three months)	$ 295		$ 295
2,016	939		939
2,017	935		935
2,018	922		922
2,019	802		802
2,020	737		737
Thereafter	1,596		1,596
Total	6,226		6,226		$ 1,582
Amortization expense	$ 284	$ 71	$ 495	$ 153

Deferred Revenue - Summary of D

Deferred Revenue - Summary of Deferred Revenue (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	$ 46,508	$ 35,688
Current portion of deferred revenue	19,628	14,020
Deferred revenue, net of current portion	26,880	21,668
Warranty
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	24,262	21,973
Current portion of deferred revenue	8,923	7,270
Deferred revenue, net of current portion	15,339	14,703
Hardware equipment
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	9,316	4,252
Current portion of deferred revenue	1,776	856
Deferred revenue, net of current portion	7,540	3,396
AXON services
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	12,570	9,286
Current portion of deferred revenue	8,569	5,717
Deferred revenue, net of current portion	4,001	3,569
Other
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	360	177
Current portion of deferred revenue	360	177
Deferred revenue, net of current portion	0	0
TASER Weapons
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	23,375	21,695
Current portion of deferred revenue	8,555	7,133
Deferred revenue, net of current portion	14,820	14,562
TASER Weapons | Warranty
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	20,617	20,400
Current portion of deferred revenue	7,244	6,591
Deferred revenue, net of current portion	13,373	13,809
TASER Weapons | Hardware equipment
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	2,398	1,118
Current portion of deferred revenue	951	365
Deferred revenue, net of current portion	1,447	753
Axon
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	23,133	13,993
Current portion of deferred revenue	11,073	6,887
Deferred revenue, net of current portion	12,060	7,106
Axon | Warranty
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	3,645	1,573
Current portion of deferred revenue	1,679	679
Deferred revenue, net of current portion	1,966	894
Axon | Hardware equipment
Deferred Revenue Arrangement [Line Items]
Total deferred revenue	6,918	3,134
Current portion of deferred revenue	825	491
Deferred revenue, net of current portion	$ 6,093	$ 2,643

Accrued Liabilities (Detail)

Accrued Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014	Dec. 31, 2013
Payables and Accruals [Abstract]
Accrued salaries and benefits	$ 2,957	$ 3,699
Accrued judgments and settlements	65	108
Accrued professional fees	330	257
Accrued warranty expense	401	675	$ 826	$ 955
Accrued income and other taxes	712	539
Other accrued expenses	2,203	3,967
Accrued liabilities	$ 6,668	$ 9,245

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) $ in Millions	9 Months Ended
	Sep. 30, 2015USD ($)
Income Tax Disclosure [Line Items]
Deferred tax assets, net	$ 16.3
Research and development tax credit studies	11.1
Unrecognized tax benefits	2.4
Deferred tax assets, valuation allowance	$ 0.4
Overall effective tax rate, after discrete period adjustments	44.00%
Effective tax rate, before discrete period adjustment	45.50%
Research and Development Credits
Income Tax Disclosure [Line Items]
Tax credit carryforward, valuation allowance	$ 1.2
Expiring in 2019
Income Tax Disclosure [Line Items]
Tax credit carryforward, amount	1.2
Federal
Income Tax Disclosure [Line Items]
Unrecognized tax benefits	2.3
State
Income Tax Disclosure [Line Items]
Unrecognized tax benefits	$ 0.1

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended
	May. 31, 2013	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	May. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Option available for future grants			1,300,000
Tax payments, for net share settlement of share based award			$ 848,000	$ 1,262,000
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation expense related to non-vested stock options			$ 15,800,000
Weighted average period			2 years 8 months 22 days
Approximate units outstanding			1,126,000		1,226,000
Performance Based Restricted Stock Unit
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Approximate units of performance restricted stock granted			36,101
Approximate units outstanding			100,000
Maximum additional shares to be issued			100,000
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares withheld, for net share settlement of share based award			33,000
Tax payments, for net share settlement of share based award			$ 800,000
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate intrinsic value price per share			$ 22.03
Total intrinsic value of options exercised			$ 13,300,000	$ 14,400,000
Number of options outstanding			1,129,000		1,641,000
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options outstanding			200,000
Unvested performance options			30,600
Unvested share, expected to vest			25,000
2013 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Additional shares authorized	1,600,000
2014 Stock Repurchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding common stock repurchase program authorized amount						$ 30,000,000
Shares repurchased during period		300,000
Cost of shares repurchased		$ 7,600,000
Average cost of shares repurchased (in USD per share)		$ 25.86
Average price of shares repurchased (in USD per share)		$ 25.83

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Restricted Stock Unit Activity (Detail) - Restricted Stock $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended
	Sep. 30, 2015USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]
Number of Units outstanding, beginning of year | shares	1,226
Number of Units, Granted | shares	400
Number of Units, Released | shares	(399)
Number of Units, Forfeited | shares	(101)
Number of Units outstanding, end of year | shares	1,126
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted Average Grant Date Fair Value, Units outstanding, beginning of year	$ 13.23
Weighted Average Grant Date Fair Value, Granted	27.24
Weighted Average Grant Date Fair Value, Released	11.23
Weighted Average Grant Date Fair Value, Forfeited	16.45
Weighted Average Grant Date Fair Value, Units outstanding, end of year	$ 18.59
Aggregate intrinsic value at year end (in thousands) | $	$ 24,801

Stockholders' Equity - Summar46

Stockholders' Equity - Summary of the Company's Stock Options Activity (Detail) - Stock Options $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended
	Sep. 30, 2015USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of options, Options outstanding, beginning of year | shares	1,641
Number of options, Granted | shares	0
Number of options, Exercised | shares	(504)
Number of options, Expired / terminated | shares	(8)
Number of options, Options outstanding, end of year | shares	1,129
Number of options, Options exercisable, end of year | shares	1,098
Number of options, Options expected to vest, end of year | shares	25
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Weighted average exercise price, Options outstanding, beginning of year	$ 5.26
Weighted average exercise price, Granted	0
Weighted average exercise price, Exercised	4.96
Weighted average exercise price, Expired / terminated	8.71
Weighted average exercise price, Options outstanding, end of year	5.36
Weighted average exercise price, Options exercisable, end of year	5.37
Weighted average exercise price, Options expected to vest, end of year	$ 4.75
Weighted average remaining contractual life, Options outstanding (in years)	3 years 7 months 5 days
Weighted average remaining contractual life, Options exercisable (in years)	3 years 7 months 10 days
Weighted average remaining contractual life, Options expected to vest (in years)	3 years 3 months
Aggregate intrinsic value, Options outstanding | $	$ 18,823
Aggregate intrinsic value, Options exercisable | $	18,299
Aggregate intrinsic value, Options expected to vest | $	$ 434

Stockholders' Equity - Reported

Stockholders' Equity - Reported Share-Based Compensation (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 1,863	$ 1,437	$ 5,086	$ 4,121
Cost of products sold and services delivered
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	118	61	276	149
Sales, general and administrative expenses
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	1,123	940	2,982	2,598
Research and development expenses
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 622	$ 436	$ 1,828	$ 1,374

Line of Credit - Additional Inf

Line of Credit - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2015USD ($)	Dec. 31, 2014USD ($)
Debt Instrument [Line Items]
Total availability under line of credit agreement	$ 10,000,000	$ 10,000,000
Letters of credit outstanding amount	3,000,000
Available borrowing under letter of credit	$ 7,000,000
Varying Interest on Line of credit agreement	LIBOR plus 1.5% or Prime less 0.75%
Maturity date of line of credit	Jul. 31, 2017
Maximum ratio of total liabilities to tangible net worth	1
Minimum required fixed coverage charge ratio	1.25
Period used for calculating ratios	12 months
Company's tangible net worth ratio	0.48
Fixed coverage charge ratio	2.53
Line of Credit | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Line of credit interest rate	1.50%
Line of Credit | Prime Rate
Debt Instrument [Line Items]
Line of credit interest rate	0.75%

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) $ in Millions	3 Months Ended
	Sep. 30, 2015USD ($)CaseLawsuit	Sep. 30, 2011Case
Commitments and Contingencies Disclosure [Abstract]
Number of lawsuits against Company | Lawsuit	15
Number of active product liability cases | Case	16	55
Schedule of Commitments and Contingencies [Line Items]
Letters of credit outstanding amount	$ 3
Expiring May 2017
Schedule of Commitments and Contingencies [Line Items]
Letters of credit outstanding amount	2.7
Expiring January 2017
Schedule of Commitments and Contingencies [Line Items]
Letters of credit outstanding amount	0.3
Surety Bond
Schedule of Commitments and Contingencies [Line Items]
Bonds outstanding	2.4
Outstanding surety bonds expected to be released during period	0.2
Surety Bond | Expiring in July 2018
Schedule of Commitments and Contingencies [Line Items]
Bonds outstanding	$ 2.2

Commitments and Contingencies50

Commitments and Contingencies - Information Regarding the Company's Insurance Coverage (Detail) $ in Millions	9 Months Ended
	Sep. 30, 2015USD ($)
2,004
Product Liability Contingency [Line Items]
Insurance Coverage	$ 2
Deductible Amount	0.1
Remaining Insurance Coverage	2
2,005
Product Liability Contingency [Line Items]
Insurance Coverage	10
Deductible Amount	0.3
Remaining Insurance Coverage	7
2,006
Product Liability Contingency [Line Items]
Insurance Coverage	10
Deductible Amount	0.3
Remaining Insurance Coverage	3.7
2,007
Product Liability Contingency [Line Items]
Insurance Coverage	10
Deductible Amount	0.3
Remaining Insurance Coverage	8
2,008
Product Liability Contingency [Line Items]
Insurance Coverage	10
Deductible Amount	0.5
Remaining Insurance Coverage	0
2,009
Product Liability Contingency [Line Items]
Insurance Coverage	10
Deductible Amount	1
Remaining Insurance Coverage	10
2,010
Product Liability Contingency [Line Items]
Insurance Coverage	10
Deductible Amount	1
Remaining Insurance Coverage	10
2,011
Product Liability Contingency [Line Items]
Insurance Coverage	10
Deductible Amount	1
Remaining Insurance Coverage	10
Jan - Jun 2012
Product Liability Contingency [Line Items]
Insurance Coverage	7
Deductible Amount	1
Remaining Insurance Coverage	7
Jul - Dec 2012
Product Liability Contingency [Line Items]
Insurance Coverage	12
Deductible Amount	1
Remaining Insurance Coverage	12
2,013
Product Liability Contingency [Line Items]
Insurance Coverage	12
Deductible Amount	1
Remaining Insurance Coverage	12
2,014
Product Liability Contingency [Line Items]
Insurance Coverage	11
Deductible Amount	4
Remaining Insurance Coverage	11
2,015
Product Liability Contingency [Line Items]
Insurance Coverage	10
Deductible Amount	5
Remaining Insurance Coverage	$ 10

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail)	3 Months Ended		9 Months Ended
	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Jul. 16, 2015USD ($)contract	Dec. 31, 2014USD ($)
Consulting | Officer
Related Party Transaction [Line Items]
Transaction expenses incurred by parent company	$ 44,000	$ 50,000	$ 156,000	$ 121,000
Outstanding payables due to related party	19,000		19,000			$ 8,000
Software Licensing and Subscription | Officer
Related Party Transaction [Line Items]
Quarterly software licensing fee	20,000
Deferred costs related to annual software subscription	$ 60,000		$ 60,000			$ 0
Non-cancellable Operating Leases | Employee
Related Party Transaction [Line Items]
Number of contracts | contract					2
Term of contract			15 years
Aggregate annual rental payments					$ 45,000

Employee Benefit Plans - Additi

Employee Benefit Plans - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Defined Benefit Plan Disclosure [Line Items]
Employee deferrals deemed vested percentage upon contribution			100.00%
Company's contributions to the plan	$ 300	$ 200	$ 900	$ 600
Company's expected contributions to the plan	$ 8		$ 31
Minimum
Defined Benefit Plan Disclosure [Line Items]
Deferral percentage of base salary			80.00%
Maximum
Defined Benefit Plan Disclosure [Line Items]
Deferral percentage of other compensation			100.00%

Segment Data - Additional Infor

Segment Data - Additional Information (Detail) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)Segment	Sep. 30, 2014USD ($)
Segment Reporting [Abstract]
Number of reportable segments of company | Segment			2
Segment Reporting Information [Line Items]
Product sales	$ 47,265	$ 43,191	$ 133,863	$ 114,972
Service revenue	3,111	1,158	7,988	2,737
Net sales	50,376	44,349	141,851	117,709
Cost of products sold	18,274	15,138	47,497	42,135
Cost of services delivered	1,034	498	2,695	1,439
Gross margin	31,068	28,713	91,659	74,135
Sales, general and administrative	17,834	12,441	47,842	39,734
Research and development	6,528	3,759	16,992	10,820
Income from operations	6,706	12,513	26,825	23,581
Purchase of property and equipment	2,069	844	3,839	2,066
Purchase of intangible assets	201	16	402	125
Purchase of property and equipment and intangible assets in connection with business acquisitions	3,005	0	12,804	0
Depreciation and amortization	948	1,101	2,310	3,368
Operating Segments | TASER Weapons
Segment Reporting Information [Line Items]
Product sales	39,520	40,010	115,686	105,160
Service revenue	0	0	0	0
Net sales	39,520	40,010	115,686	105,160
Cost of products sold	12,445	12,443	34,805	34,024
Cost of services delivered	0	0	0	0
Gross margin	27,075	27,567	80,881	71,136
Sales, general and administrative	11,941	10,028	33,469	32,218
Research and development	1,151	1,050	3,418	2,660
Income from operations	13,983	16,489	43,994	36,258
Purchase of property and equipment	1,900	803	2,435	1,836
Purchase of intangible assets	114	14	195	123
Purchase of property and equipment and intangible assets in connection with business acquisitions	1,503	0	1,503	0
Depreciation and amortization	603	1,010	1,689	3,078
Operating Segments | Axon
Segment Reporting Information [Line Items]
Product sales	7,745	3,181	18,177	9,812
Service revenue	3,111	1,158	7,988	2,737
Net sales	10,856	4,339	26,165	12,549
Cost of products sold	5,829	2,695	12,692	8,111
Cost of services delivered	1,034	498	2,695	1,439
Gross margin	3,993	1,146	10,778	2,999
Sales, general and administrative	5,893	2,413	14,373	7,516
Research and development	5,377	2,709	13,574	8,160
Income from operations	(7,277)	(3,976)	(17,169)	(12,677)
Purchase of property and equipment	169	41	1,404	230
Purchase of intangible assets	87	2	207	2
Purchase of property and equipment and intangible assets in connection with business acquisitions	1,502	0	11,301	0
Depreciation and amortization	$ 345	$ 91	$ 621	$ 290

Business Acquisitions (Details)

Business Acquisitions (Details) - USD ($) $ in Thousands	Jul. 16, 2015	May. 05, 2015	Sep. 30, 2015	Dec. 31, 2014
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Goodwill			$ 9,313	$ 2,206
MediaSolv Solutions Corporation
Business Acquisition [Line Items]
Consideration transferred		$ 8,823
Cash acquired		100
Payments to acquire businesses, net		7,800
Contingent liability		1,000
Additional earn-out provisions and compensation adjustments		$ 4,000
Intangible assets, weighted average useful life (in years)		6 years 6 months
Acquisition transaction costs		$ 200
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Accounts receivable and other current assets		590
Inventory		35
Property and equipment		53
Intangible assets		4,145
Goodwill		5,600
Accounts payable and accrued liabilities		(403)
Deferred revenue		(153)
Deferred income tax liabilities, net		$ (1,044)
Tactical Safety Responses Limited
Business Acquisition [Line Items]
Consideration transferred	$ 3,334
Cash acquired	$ 700
Intangible assets, weighted average useful life (in years)	7 years
Acquisition transaction costs	$ 100
Cash payments to acquire business	4,000
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Accounts receivable and other current assets	726
Inventory	497
Property and equipment	583
Intangible assets	881
Other Assets	20
Goodwill	1,541
Accounts payable and accrued liabilities	(207)
Notes payable	(169)
Deferred income tax liabilities, net	$ (538)